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ABSTRACT 
Hot flushes, the most characteristic symptoms in menopause, are 
encountered by c.a. 80% of women. Hot flushes and other menopausal 
complaints can significantly impair a woman’s quality of life. It is, however, 
unclear why some women experience intolerable hot flushes while others 
remain completely asymptomatic. Hot flushes are characterised by 
cardiovascular reactions such as rapid episodes of reddening of skin and 
palpitations. Thus, women with or without hot flushes may differ in their 
cardiovascular reactivity regulated by the autonomic nervous system and 
responses to hormone therapy. Moreover, hot flushes have been discussed as 
one explanation for the differing results of hormone therapy’s cardiovascular 
health effects. 
The present study was designed to investigate the impact of hot flushes 
and different forms of hormone therapy on health-related quality of life. The 
relationship between a history of premenstrual symptoms and the 
postmenopausal quality of life and hot flushes was also assessed. The aim of 
this research was to explore the effects of hot flushes on the cardiovascular 
autonomic function before and during hormone therapy.  
The cardiovascular autonomic function was studied in 150 healthy, 
recently postmenopausal women with a standardised test series in controlled 
laboratory settings. Women showed a large variation in hot flushes, which 
were evaluated prospectively with a two-week hot flush diary. 
Hot flushes impaired health-related quality of life in menopause, but had 
little effect on the women’s sexual wellbeing. A history of premenstrual 
symptoms did not predict the severity of postmenopausal hot flushes, but 
was associated with poor sleep, depressive feelings, and impaired memory 
and concentration in menopause. Women with hot flushes had non-
significantly lower increases in blood pressure in response to isometric 
muscle contraction than women without hot flushes. Women with hot flushes 
reacted with more tachycardia during the Valsalva manoeuvre and with 
slightly blunted parasympathetic activity in heart rate responses to active 
orthostatic testing compared with asymptomatic women.  
In the six-month hormone therapy trial, women with or without hot 
flushes were treated in a double-blind randomised setting with transdermal 
estradiol hemihydrate gel (1mg/day), oral estradiol valerate (2 mg/day) alone 
or in combination with medroxyprogesterone acetate (5 mg/day), or with a 
placebo. 
All hormone therapy regimens alleviated hot flushes and other 
menopausal symptoms equally effectively, but did not affect sexual 
wellbeing. In women with pre-treatment hot flushes, hormone therapy 
improved the health-related quality of life in terms of sleep, anxiety and 
fears, memory and concentration, and general health compared with those 
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receiving a placebo. Hot flushes were accompanied with lowered resting 
blood pressures but increases in blood pressure responses to isometric 
muscle contraction during all hormone therapy regimens. Resting diastolic 
blood pressure was lower during estradiol treatment (oral or transdermal) in 
women with pre-treatment hot flushes compared with non-flushing women. 
In women with pre-treatment hot flushes estradiol treatment reduced the 
resting heart rate compared with placebo treatment. This effect was 
attenuated by medroxyprogesterone acetate in treatment. Hot flushes 
associated with reduced maximal heart rate in response to isometric muscle 
contraction during estradiol treatment, yet the addition of 
medroxyprogesterone acetate also eliminated this effect. In women with hot 
flushes, hormone therapy reduced very low frequency power during 
controlled breathing compared with baseline level and with non-flushing 
women. Otherwise, hormone therapy did not affect heart rate variability. 
In conclusion, premenstrual symptoms do not predict troublesome hot 
flushes, but do associate with impaired quality of life in menopause. Hot 
flushes impair the health-related quality of life, but can be effectively 
alleviated with hormone therapy. Hot flushes seem to associate with slightly 
pronounced sympathetic responses in autonomic regulation of heart rate and 
blood pressure. This potentially unfavourable activity can be reduced with 
estradiol treatment in women with hot flushes, who initiate hormone therapy 
in clinical practice. Progestin-containing hormone therapy blunted or even 
converted the positive effects of estradiol on heart rate regulation. Thus, the 
hot flush status contributes markedly to the quality of life and cardiovascular 
autonomic function before and during hormone therapy. Particularly women 
with hot flushes appear to benefit most from the positive effects of hormone 
therapy on the health-related quality of life and cardiovascular regulation. 
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INTRODUCTION 
Women reach menopause at the mean age of 51. Approximately every 
three out of four women experience menopausal symptoms, which can 
significantly deteriorate the quality of life. Typical menopausal symptoms 
include vasomotor hot flushes, night sweats, broken sleep, mood swings, 
muscle and joint pain, and impaired memory and concentration (Nelson 
2008). Many of the menopausal symptoms resemble premenstrual symptoms, 
which are complained about by up to 80% of women in fertile age (Deecher & 
Dorries 2007). Thus, menopausal and premenstrual symptoms might share 
similar underlying attributes. In clinical practice, women with premenstrual 
symptoms may often worry whether they also have an increased risk for 
troublesome menopausal hot flushes.  
Despite substantial investigation, the exact etiology of hot flushes, the 
most characteristic symptoms in menopause, has remained unclear. One 
plausible mechanism is thermoregulatory imbalance at the hypothalamic 
level arising from menopausal hypoestrogenism (Freedman 2005). Since the 
autonomic nervous system also regulates the thermal balance of the body, 
the role of the autonomic function changes in hot flush physiology is under 
active research (Hoikkala et al. 2010, Thurston et al. 2010a, Freedman et al. 2011, 
Thurston et al. 2012, de Zambotti et al. 2013). Hot flushes have been associated 
with a worsened cardiovascular disease (CVD) risk profile in some (Gast et al. 
2008, Thurston et al. 2008, Thurston et al. 2010b, Thurston et al. 2011a), but not 
all (Tuomikoski et al. 2009a, Hitchcock et al. 2012, Wolff et al. 2013) studies. The 
autonomic nervous system is the main regulator of the cardiovascular 
system. The sympathetic and parasympathetic branches reciprocally control 
blood pressure, heart rate, cardiac function, and the vascular bed 
maintaining homeostasis in the body. The cardiovascular autonomic 
regulation is altered along aging and at menopause; sympathetic activity 
increases and parasympathetic decreases (Brockbank et al. 2000, Lavi et al. 
2007, Vongpatanasin 2009). Whether these changes are associated with 
menopause itself or menopausal symptoms is not known. 
Hot flushes and other menopausal symptoms have been treated with 
estrogen therapy (ET) for over 70 years. About a decade ago, the differing 
findings between former observational (Grady et al. 1992, Grodstein 1996, 
Grodstein et al. 2000, Stram et al. 2011) and randomised controlled studies 
(Hulley et al. 1998, Cherry et al. 2002, Grady et al. 2002a, Rossouw et al. 2002) led 
to a debate concerning the cardiovascular safety of hormone therapy (HT). 
The randomised controlled studies in women without hot flushes did not 
confirm the beneficial effects of HT on CVD risk seen in the previous 
observational studies. Later on, these differing results have been widely 
discussed and the timing of HT, various HT formulations, the role of 
progestogen versus estrogen only therapy, and different administration 
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routes have been suggested as possible explanations for the divergent results 
(Mikkola & Ylikorkala 2005, Clarkson et al. 2013, Harman 2014, Tuomikoski & 
Mikkola 2014). The importance of hot flushes as one possible explanation has 
arisen (Tuomikoski et al. 2011).  
The present studies were designed to explore the association of 
premenstrual and menopausal complaints and the potential impact of hot 
flushes on cardiovascular autonomic function and quality of life before and 
after six months of different types of postmenopausal HT. 
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REVIEW OF THE LITERATURE 
General aspects of menopause 
Menopause, defined as the final menstrual period, is the natural ending of 
a woman’s reproductive life.  Natural menopause is defined as spontaneous 
cessation of menstruation for twelve consecutive months (McKinlay et al. 
1992). Normally, menopause occurs between ages 45 to 55, and the 
menopausal transition can last for several years (Soules et al. 2001, Butler & 
Santoro 2011). The time period preceding menopause is characterised by low 
or lacking concentration of progesterone and rising levels of the follicle 
stimulating hormone (FSH), often leading to cycle irregularities (Kase 2009). 
Along with FSH, secretion of the luteinizing hormone rises and the estradiol 
(E2) level slowly declines, finally reaching the hypoestrogenic state of 
postmenopause (Anttila & Salmi  2004). In clinical practice, an FSH level over 
30 IU/l is considered postmenopausal, but it is known to fluctuate around 
the menopause (Anttila et al. 1991). The circulating levels of the FSH and the 
luteinizing hormone remain high for several years after menopause and the 
latter also stimulates the androgen production from the ovaries.  
Due to fluctuating estrogen levels, most perimenopausal women 
encounter typical symptoms such as hot flushes, night sweats, mood swings, 
palpitations, joint and muscle aches, poor sleep, and impaired memory or 
concentration (Freeman et al. 2007, Nelson 2008) (Table 1). Some of these 
symptoms, such as poor sleep, may be secondary to hot flushes (Freedman 
2014). Long-term changes after menopause include, e.g., atrophy of the 
vaginal epithelium (Santoro & Komi 2009, Kingsberg et al. 2013), degradation of 
connective tissues  (Calleja-Agius & Brincat 2012) and bone loss (Waugh et al. 
2009). Hot flushes and other menopausal symptoms are bothersome and 
thus, up to 75% of women seek medical advice from health care professionals 
(Carpenter et al. 2011). 
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Table 1. Typical menopausal symptoms. 
 
Subjective 
 
Objective 
 
 
Hot flushes 
 
Vaginal atrophy 
Night sweats Osteopenia 
Palpitations Osteoporosis 
Poor sleep Pelvic floor defects 
Depressive symptoms Urine control problems 
Headaches Degradation of connective tissues and skin 
Difficulty concentrating  
Poor memory  
Joint aches  
Irritability  
Nervousness  
Anxiety  
 
 
Despite the longer life expectancy the mean age at menopause has 
remained the same (Gold et al. 2001, Kase 2009). In Finland women reach 
menopause at 51 years of age on average and in 2013 there were over 1.1 
million Finnish women in the age group of 51 years or older (Tilastokeskus 
2014). The number of postmenopausal women is increasing in Finland and 
other western countries as the population ages. Smoking (Gold et al. 2001, 
Parente et al. 2008), low socioeconomic status (Gold et al. 2006), and 
hysterectomy (Farquhar et al. 2005) have been linked with earlier menopause. 
Association between menopausal age and nulliparity, low number of 
pregnancies, use of oral contraceptives, or low body mass index have 
remained inconclusive (Gold et al. 2001). Furthermore, some studies have 
reported ethnical differences in age of natural menopause: Far-Eastern and 
Japanese women reach their menopause later and Afro-American women 
earlier than Caucasian women (Bromberger et al. 1997, Gold et al. 2001, 
Richard-Davis & Wellons 2013). This could have important clinical 
implications, since younger age at menopause associates with an elevated 
risk of CVD (Archer 2009, Stuenkel 2012, Wellons et al. 2012), osteoporosis 
(Gallagher 2007, Shuster et al. 2010), and shorter life expectancy (Cooper & 
Sandler 1998).  
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Health-related quality of life 
Health-related quality of life (HRQL) is defined as a person’s perception 
of one’s physical, cognitive, and mental health (Utian & Woods 2013). During 
the menopausal transition, HRQL is generally decreased, mainly due to 
menopausal complaints such as hot flushes, mood alterations, poor sleep, 
impaired memory, and sexual dysfunction. Furthermore, the risk of 
developing depressive symptoms in perimenopause is increased (Llaneza et 
al. 2012), but association between hot flushes and depressive symptoms is 
unclear. 
Postmenopausal women often complain of impaired memory and 
concentration, which may decrease HRQL (Weber et al. 2013a). Menopausal 
transition seems to have a temporary negative impact on cognition, but no 
clear long term effects (Greendale et al. 2009, Henderson 2011, North American 
Menopause Society 2012). Data on the association between deterioration of 
memory and hot flushes are controversial (LeBlanc et al. 2007, Maki et al. 2008, 
Greendale et al. 2010, Schaafsma et al. 2010, Mitchell & Woods 2011). Since 
estrogen has direct effects on the brain (Resnick et al. 2006), cognitive decline 
in the perimenopause may be independent from hot flushes, sleep 
disturbances or depressive symptoms (Weber et al. 2013b). Still, the decline of 
HRQL during menopause and the role of hot flushes in this have remained 
unclear.    
Sexual dysfunction due to troubling symptoms, such as vaginal and vulvar 
atrophy, decreased vaginal lubrication, and possibly diminished libido, may 
impair HRQL in menopause. Additionally, psychological and relationship 
factors determine the individual experience of the menopause, which all 
affect the sexual well-being and HRQL of women (Bachmann & Leiblum 2004, 
Nappi et al. 2010). 
Multiple validated questionnaires should be used in studies on HRQL 
(Nachtigall 2009). The HRQL questionnaires are often divided into two types: 
generic and specific. Generic HRQL questionnaires (e.g. SF-36, Rand-36, 
EuroQOL EQ-5D, 15D) are applicable across a wide range of population and 
interventions, whereas specific questionnaires are designed for particular 
subpopulations or interventions (Coons et al. 2000). Furthermore, 
menopause-specific HRQL questionnaires are recommended for midlife 
women. For example, the Women’s Health questionnaire (WHQ) (Hunter 
1992) is age-specific (45 to 65 years) and validated reflecting the effects of 
menopausal symptoms on HRQL (Hunter 2000) (Appendix A). Additionally, 
there are other menopause-specific HRQL questionnaires, such as the 
Greene Climacteric scale (Greene 1976) and the Menopause Rating Scale 
(Schneider et al. 2000). Although both of these scales (Greene Climacteric 
scale, Menopause Rating Scale) are validated (Utian & Woods 2013), they are 
not widely used in HRQL studies.  
The Kupperman Index is an example of a traditional menopause-related 
symptom list. It was originally developed to investigate the efficacy of 
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different hormonal preparations (Kupperman et al. 1953), but has been 
modified over the decades. It measures symptoms as a menopausal index, a 
sum of symptom points weighted according to their prevalence (the higher 
the score, the worse the menopausal symptoms) (Appendix B). In addition, 
subjective perception of one’s general health and well-being can be evaluated 
with a visual analogue scale (VAS), ranging from the worst imaginable state 
to the best imaginable state (scale from 0 to 100) (Welton et al. 2008) 
(Appendix C). This VAS is a part of the validated European Quality of Life 
questionnaire (Euro QOL) (Jenkinson et al. 1997). A specific question of 
general health compared with one year ago also describes subjective 
perception of the current HRQL (Appendix C). It is included in the Rand 36-
Item Health Survey (Rand-36) and has been used separately, for example, in 
the WHI study (Hays et al. 2003, Brunner et al. 2005). 
Although some menopause-specific HRQL questionnaires also address 
sexual function matters, many instruments have been developed specifically 
for evaluating sexuality. Three types of self-report measures are available: 
self-administered questionnaires, diaries, and structured interviews (Rosen 
2001). Typically, female sexual functioning is assessed in the areas of desire, 
arousal, orgasm, partner factors, and sexual pain (Bachmann & Leiblum 2004).  
These areas are thoroughly covered in the McCoy Female Sexuality 
Questionnaire (MFSQ) (Appendix D), which is designed and validated to 
measure aspects of female sexuality during menopausal transition (McCoy & 
Davidson 1985). Other questionnaires are also available, such as the Female 
Sexual Function Index (Rosen et al. 2000), the Female Sexual Function 
Inventory (Berman et al. 1999), and the Brief Index of Sexual Functioning for 
Women (Mazer et al. 2000). 
  
Hot flushes 
Hot flushes are the most characteristic symptoms during the menopause, 
also often referred to as vasomotor symptoms or hot flashes in American 
literature. Up to 80% of women report hot flushes of different severity 
(Nelson 2008). The flushing usually peaks at one year after final menstruation 
and subsides with increasing age, but it can last for several years. Sometimes 
the symptoms can re-start after treatment cessation (Ockene et al. 2005). 
Some women start or continue to have vasomotor symptoms later on after 
menopause in their 60s or even 70s (Barnabei et al. 2002, Hunter et al. 2012).  
Women show great variation in hot flushes (none to severe), and a 
familial tendency is apparent (Staropoli et al. 1998, Murabito et al. 2005), which 
has led to several suggestions for the background mechanisms. One 
suggested explanation is the diversity in genes guiding estrogen metabolism 
or estrogen receptors (Miller et al. 2008). Furthermore, many social and 
cultural factors, such as socioeconomic status, marital status, diet, and 
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attitude affect women’s coping styles. Even ethnic differences in menopausal 
symptoms are seen; Asian women experience less symptoms than other 
ethnic groups and African Americans have more vasomotor symptoms than 
Caucasian women (Gold et al. 2006, Miller et al. 2006, Freeman & Sherif 2007, 
Richard-Davis & Wellons 2013). The role of body mass in the subjective 
experience of hot flushes has remained controversial (Thurston et al. 2011b, 
Thurston & Joffe 2011). Latest results conclude that obese women encounter 
more hot flushes, cycle irregularities and heavy bleeding in the 
premenopausal stage, but after the final menstrual period, obese women are 
less likely to experience hot flushes than their lean counterparts (Butler & 
Santoro 2011).  
The assessment of hot flushes varies greatly, and in many studies women 
answer only one or a few questions whether they have experienced hot 
flushes during the past months or years. This retrospective method is subject 
to recall bias. Hot flushes should be registered prospectively for one to two 
weeks to obtain reliable information and both the severity and frequency 
should be rated (Loprinzi et al. 2009), because hot flushes show considerable 
day-to-day variation (Sloan et al. 2001). There are several hot flush rating 
scales for scientific and clinical purposes, of which the Hot Flush Weekly 
Weighted Symptom score (HFWWS) is an established and validated 
questionnaire (Sloan et al. 2001)(Table 9, p. 45). For research purposes, it has 
been proposed that sternal skin conductance measurement should be used 
for quantifying hot flushes in clinical trials (Carpenter et al. 2004). This 
method, however, is prone to errors, because other sweating or sympathetic 
activation can be misinterpreted as hot flushes. Therefore, current opinion 
recommends the use of prospective hot flush diaries that are based on a 
woman’s subjective evaluation of her hot flushes, as in clinical practice when 
initiation of HT is considered (Loprinzi & Barton 2009).  
A hot flush can vary from a mild sensation of warmth to a strong 
sensation of heat throughout the body with extensive perspiration, reddening 
of the skin, palpitation, and anxiety. One hot flush usually lasts less than five 
minutes (Nelson 2008). During a hot flush, the sensation of heat starts 
typically in the chest area or upper trunk and spreads upwards. The 
frequency of flushing varies individually, ranging from a few per month to 
several flushes per hour.  Hot flushes associate with typical physiological 
changes, such as increased skin blood flow and heart rate (Sturdee 2008).  
Etiology of hot flushes has remained unknown. Hot flushes are related to 
changes in the hypothalamic thermoregulation and associate with a 
narrowed thermoneutral zone in regulation of the core body temperature 
(Freedman 2005). The lowering levels of estrogens are followed by decreased 
endorphin concentrations in the hypothalamus, which increases the release 
of serotonin and noradrenalin. These neurotransmitters lower the set point 
in the thermoregulatory nucleus, which causes heat loss during hot flushes 
(Freedman 2005, Archer et al. 2011). Heat loss from the skin is regulated by the 
autonomic nervous system. As part of the thermoregulation of the body, the 
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sympathetic nervous system controls cutaneous vasomotor activity and 
sweating. In studies concerning the mechanisms of vasomotor symptoms, 
skin blood flow and sympathetic nerve activity have increased during hot 
flushes (Low et al. 2008), and women with vasomotor symptoms have shown 
elevations in sympathetic activity (Deecher & Dorries 2007, Sturdee 2008, 
Freedman et al. 2011). Since the autonomic nervous system is the main 
regulator of the peripheral vasculature, it may contribute to the mechanisms 
behind postmenopausal hot flushes. Interestingly, altered function of the 
autonomic nervous system has also been suggested as a possible underlying 
mechanism behind premenstrual symptoms (Palmero & Choliz M 1991, 
Girdler et al. 1998).  
Resemblance of menopausal symptoms with 
premenstrual symptoms 
Premenstrual symptoms of variable severity have been reported in up to 
80% of women (Halbreich 2003). These symptoms are most common in 
women in their thirties and forties but they can affect women’s HRQL from 
the teen age years through to the menopause. Typical premenstrual 
symptoms include irritability, anxiety or depressive mood, tiredness, 
sleeping problems, overeating, headache, breast tenderness and bloating 
(Halbreich 2004) (Table 2). Women may have only a single symptom or a 
cluster of related symptoms. Women with significantly impairing symptoms 
are diagnosed with premenstrual syndrome (PMS) (Halbreich et al. 2007).  
The pattern of symptom manifestation is essential for PMS diagnosis. 
Patients typically experience symptoms in the luteal phase of the menstrual 
cycle, and once menstruation begins they disappear. According to diagnostic 
criteria, these symptoms should also cause significant impairment to daily 
life. Premenstrual syndrome affects 30-40% of the reproductive female 
population (Baker & O'Brien 2012, Direkvand-Moghadam et al. 2014). A 
particularly severe form of PMS is premenstrual dysphoric disorder (PMDD) 
with an emphasis on the affective symptoms. It is diagnosed in 
approximately 1-8% of women (Halbreich 2003, Gehlert et al. 2009, Biggs & 
Demuth 2011).  
The etiology of premenstrual symptoms is not clearly understood (Biggs & 
Demuth 2011), and it is most probably multifactorial (Halbreich 2003, Yonkers 
et al. 2008). The proposed underlying mechanisms are various, such as, 
fluctuation in gonadal hormones, their metabolites and interactions with 
neurotransmitters (Halbreich 2003). Possibly, the normal gonadal hormone 
fluctuations during the menstrual cycle trigger an abnormal serotonergic 
response in the ‘vulnerable’ women. Autonomic regulation has also differed 
in women with severe premenstrual symptoms that are seen as decreased 
parasympathetic activity compared with asymptomatic women (Matsumoto et 
al. 2006, Matsumoto et al. 2007). Moreover, autonomic activity seems to vary 
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across the normal menstrual cycle. Some studies show increased sympathetic 
activity (Sato et al. 1995, Guasti et al. 1999, Yildirir et al. 2002), whereas others 
show increased parasympathetic activity (Fuenmayor et al. 2000, Princi et al. 
2005) in the luteal phase compared with the follicular phase. Other studies 
have not found differences in autonomic activity during the phases of the 
menstrual cycle (Leicht et al. 2003, Nakagawa et al. 2005). Thus, the autonomic 
regulation in the etiology of premenstrual symptoms remains unclear. 
Table 2.  Typical premenstrual symptoms. 
 
Psychological 
 
Physical 
Anger/Irritability Breast tenderness/swelling 
Depression Weight gain 
Anxiety Bloating 
Mood swings Headache 
Anhedonia Joint pain 
Poor sleep Muscle pain 
Decreased interest in home/social/work activities  
Lethargy  
Concentration difficulties  
Overeating/Cravings  
 
 
The fact that both premenstrual and postmenopausal symptoms share 
similar features, such as mood swings, sleeping problems and muscle and 
joint pain, has initiated research on the possible association between these 
symptoms. Premenstrual symptoms and a more troublesome perimenopause 
have associated in some (Collins & Landgren 1994, Morse et al. 1998, Freeman et 
al. 2004), but not in all studies (Guthrie et al. 1996) (Table 3). Premenstrual 
symptoms have been associated especially with psychological distress in 
postmenopause (Stewart & Boydell 1993, Morse et al. 1998). The possible 
association between premenstrual symptoms and hot flushes, however, 
remain unclear.  
Many validated prospective screening questionnaires and charts of 
premenstrual symptoms exist, for example the Daily Record of Severity of 
Problems chart (Endicott et al. 2006). In retrospective assessment of 
premenstrual symptoms, the International Society for Premenstrual 
Disorders Montreal consensus statement (O'Brien et al. 2011) recommends 
the Premenstrual Symptom Screening Tool (PSST) (Steiner et al. 2003). This 
consists of a comprehensive premenstrual symptom list and questions about 
how premenstrual symptoms impair working capacity, social activities, home 
responsibilities or personal relationships rated on a severity scale (Appendix 
E). 
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Table 3.  Previous studies on associations between premenstrual symptoms and 
menopausal complaints. 
 
Research/author Methods Association to 
previous PMS (+/-) 
 Premenstrual 
symptoms 
Menopausal 
symptoms 
 
+ = association 
 - = no association 
Stewart & 
Boydell 1993 
n=86 
Self-report 
questionnaire of  
previous PMS 
and other 
diagnoses 
-Psychological 
distress 
-Brief Symptom 
Inventory 
psychological 
distress in 
menopause + 
Collins & 
Landgren 1994 
n=1324 
 
Self-report 
questions about 
premenstrual 
symptoms 
Menopause 
Symptom Inventory 
vasomotor 
symptoms + 
 
Guthrie et al. 
1996 
n=438 
 
1 question 
retrospectively 
2 questions  
(past 2 weeks) 
hot flushes – 
E2 – 
FSH – 
(in the post- 
menopausal group) 
Morse et al.  
1998 
n=291 
Womens’ own 
list of complaints 
fitted to 
MDQ=Menstrual 
Distress 
Questionnaire 
Menopause-related 
symptoms  
(past 2 weeks) 
hot flushes – 
dysphoria + 
skeletal + 
digestive + 
respiratory + 
Freeman et al. 
2004 
n=320 
2 questions  
(with severity 
rating) 
-hot flushes 
(frequency and 
severity,  past 1 
month) 
-depressive 
symptoms (20-item 
inventory) 
-sleep 
-libido 
hot flushes + 
depressed mood + 
decreased libido + 
poor sleep + 
E2 = Estradiol, FSH = Follicle stimulating hormone, PMS = Premenstrual syndrome 
 
Premenstrual symptoms can be treated with psychotropic, hormonal, and 
even with surgical methods (Baker & O'Brien 2012). Selective serotonin 
reuptake inhibitors are the drug of choice for severe PMS and PMDD, since 
improvement of both psychological and somatic symptoms have been 
demonstrated in several studies (Dimmock et al. 2000, Freeman et al. 2001, 
Bethea et al. 2002).   
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The hormonal treatment of premenstrual symptoms is based on ovulation 
suppression, and for this oral combined contraceptive pills are commonly 
used (Rapkin 2003). Oral contraceptives containing drospirenone have shown 
an advantage over other oral contraceptives due to drospirenone’s 
antiandrogenic and antialdosteronic properties (Pearlstein et al. 2005, Anttila 
et al. 2011). Near menopause, a combination of transdermal estrogen and a 
levonorgestrel releasing intrauterine device is recommended for treatment of 
PMS (Baker & O'Brien 2012). 
 
Risk for cardiovascular disease 
Cardiovascular disease, which is the leading cause of morbidity and 
mortality in both women and men in the Western world (Mosca et al. 2011, 
Mikkola et al. 2013), can manifest as coronary heart disease, myocardial 
infarction, transient ischemic cerebral attacks or stroke. Over the past 
decades, women’s cardiovascular risk profile has worsened (Towfighi et al. 
2009), and thus, mortality for CVD causes in women is higher than in men 
(Collins et al. 2007, Shaw et al. 2009). A large body of epidemiological evidence 
demonstrates that women’s risk for CVD elevates after the menopause 
compared with age-matched men (Go et al. 2013, Miller et al. 2013), but the 
data are not completely uniform (Barrett-Connor 1997, Vaidya et al. 2011). 
Recent findings of a large Finnish population study show that CVD mortality 
in men accelerates at a relatively young age, but in women, the risk shows a 
steep increase around 60 years of age (Mikkola et al. 2013). Thus, it is highly 
important to identify and improve CVD risk factors in women at their mid-
life years (Puurunen et al. 2011). 
The menopause-induced hypoestrogenism is the most plausible 
explanation for this sex-specific change in the CVD incidence (Collins 2001, 
Mendelsohn & Karas 2005, Vitale et al. 2009, Mikkola et al. 2013). This theory 
gains support from studies associating premature or early menopause and 
the subsequent prolonged hypoestrogenism with an elevation in age-adjusted 
risk for CVD (Atsma et al. 2006, Archer 2009, Shuster et al. 2010). 
Hypoestrogenism may promote vascular inflammation, endothelial 
dysfunction (Ylikorkala et al. 1998, Novella et al. 2012) and development of an 
atherogenic lipid profile (Tikkanen 1996, Rosano et al. 2007).  
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Postmenopausal hormone therapy  
Menopausal symptoms have been treated with ET for over seven decades 
(Stefanick 2005). Current guidelines recommend estrogen as the most effective 
treatment to alleviate vasomotor symptoms and other menopausal 
complaints (Duodecim konsensuslausuma 2005, Skouby et al. 2005, Santen et al. 
2010, North American Menopause Society 2012). Estrogen is also used for the 
prevention of osteoporosis (Santen et al. 2010, Tuppurainen et al. 2010, Sturdee 
et al. 2011, Osteoporoosi: Käypä hoito - suositus 2014), as estrogen deprivation 
leads to the deterioration of both bone structure and bone mineral density 
after menopause. In the USA, conjugated equine estrogens (CEE) are 
commonly used in HT, whereas in Europe, mainly 17β-estradiol is used, and 
this is also the only available systemic estrogen in Finland. Since the use of 
unopposed ET is associated with an increased risk of endometrial cancer, 
combination therapy with progestin (EPT) is required for endometrial 
protection if a woman has an intact uterus. In the USA CEE is most often 
combined with medroxyprogesterone acetate (MPA), whereas in Europe, a 
large variety of progestins are available for EPT. 
The primary indication for HT is alleviation of moderate or severe hot 
flushes. Initiation of HT is always an individual’s decision after weighing the 
risks and benefits with her doctor. Generally accepted contraindications of 
HT are a history of breast cancer, venous thromboembolism, untreated 
hypertension, heart failure, severe liver disease, systemic lupus 
erythematosus, and vaginal bleeding of unknown origin. The 
recommendations for HT suggest treatment with the lowest effective dose for 
the shortest possible time (Duodecim konsensuslausuma 2005, Skouby et al. 2005, 
Santen et al. 2010). Sole ET has a more favorable risk-benefit profile (Skouby et 
al. 2005, Santen et al. 2010, Sturdee et al. 2011, North American Menopause Society 
2012) (Table 4). Current guidelines suggest an individual evaluation of the 
menopausal symptoms every 2 to 3 years and consideration of HT 
continuation. 
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Table 4. Risks and benefits of postmenopausal hormone therapy. 
 
Postmenopausal hormone therapy 
(Number of cases/10 000 person years) 
 
Benefits  Risks  
Bone fracture      ET: -56 
EPT: -46 
Breast cancer 
 
ET: -8 
EPT: +8 
 
Coronary heart 
events  
 
ET: -3 
EPT: +6 
Stroke (> 60 years) #  
 
ET: +11 
EPT: +9 
Diabetes               EPT: -15 Venous thrombosis # 
 
ET: +7 
EPT: +12 
 
Colon cancer          EPT: -6 Gallbladder disease  ET: +33 
EPT: +20 
 
  Urinary incontinence 
 
ET: +1271 
EPT: +872 
 
    
# not with transdermal administration  
Based on (Mikkola 2012) and (Nelson et al. 2012) review including 9 trials, most of 
the results reported from the WHI trial 
ET=Estrogen therapy 
EPT= Estrogen-progestogen therapy 
Estrogens 
The three natural estrogens of the human body are E2, estrone, and 
estriol, of which E2 is the most potent one. Estrone carries approximately 4% 
of the estrogenic activity of E2. Estradiol is produced mainly by the growing 
ovarian follicles and the corpus luteum, the placenta, and adrenals, but also 
in the liver, endometrium, brain, muscle, and adipose tissue. There is 
conversion between the hormonally active 17β-estradiol and the weak 
estrone and their sulfates. In the postmenopause, estrone is the main 
estrogen of the body produced by aromatization in the adipose tissue. Only 
2% of the circulating estrogens are free and active, whereas the majority are 
bound to the serum proteins, such as the sex hormone binding globulin and 
albumin (Kuhl 2005). 
 Estrogen receptors are found throughout the body, e.g., the reproductive 
organs, breast, muscle, and bone tissues, the brain, blood vessels (vascular 
smooth muscle and endothelial cells), the heart, and also in the coronary 
arteries (Kuhl 2005, Turgeon et al. 2006, Ling et al. 2006). There are at least 
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three receptors: the nuclear ERα and ERβ are based on genomic 
mechanisms, and the third receptor in the cell membrane acts by rapid non-
genomic mechanisms (Miller et al. 2008).  
The hormonal potency of estrogens is measured by their affinity to 
receptors and the intracellular concentration of estrogen. This potency is 
dependent on the free fraction of the circulating estrogen.  The CEE is a 
natural mixture of estrogen sulfates extracted from the urine of pregnant 
mares, and therefore the composition and potency may vary. The most 
potent estrogen in the CEE is equilin, but it contains both E2 and estrone, 
which humans also produce. The estrogenic potency of CEE is considerably 
higher compared with E2 (Kuhl 2005), and approximately 0.625 mg of oral 
CEE is equivalent to 2 mg of oral E2. 
Progestogens 
Natural progesterone is produced mainly in the corpus luteum and the 
placenta.  Albumin binds 80% of the circulating progesterone with low 
affinity, and 17% is bound to corticosteroid-binding globulin with high 
affinity, while only 3% remains free. Synthetic progestins applied in HT are 
derivatives of progesterone, 19-norprogesterone, 19-nortestosterone 
(testosterone), or spironolactone (Sitruk-Ware 2008). They differ widely in 
their hormonal pattern with estrogenic, androgenic or antiandrogenic, 
glucocorticoid, and antimineralocorticoid actions (Table 5) (Kuhl 2005, 
Schindler et al. 2003, Nath et al. 2009).  
In women with an intact uterus, progestogens are required in HT to 
inhibit the estrogen-induced proliferation of the endometrium. This 
antiestrogenic effect is characterised with the ‘transformation dose’ reflecting 
the dose needed to cause full secretory transformation of the proliferated 
endometrium. The biological effects of progestogens are generally dependent 
on the presence of estrogens. Progesterone has two main types of receptors, 
PRA and PRB, but it additionally acts by rapid non-genomic interactions 
with membrane binding sites (Kuhl 2005). The receptors are found 
throughout the body, including the cardiovascular and central nervous 
systems. 
Medroxyprogesterone acetate is a 17-OH-progesterone derivative, which 
has a 100% bioavailability after oral administration, as it does not undergo 
inactivation during the first-pass metabolism. Most of MPA (88%) is bound 
to albumin in the circulation, and it is partly stored in the adipose tissue. 
Common doses administered in postmenopausal HT are 5-10 mg daily 
during sequential or cyclic therapy and 2,5 mg during continuous combined 
therapy. Medroxyprogesterone acetate possesses weak androgenic properties 
and considerable glucocorticoid effects (Herkert et al. 2001). It has been the 
progestin component in many HT studies. 
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Table 5. Biological activity of progestogens available for hormone therapy in Finland.  
              (+ effective, ± weakly effective, - none) 
 
Progestogen Estogenic Anti- 
estrogenic 
Andro-
genic 
Anti- 
androgenic 
Anti- 
mineralo- 
corticoid 
Gluco- 
corticoid 
Progesterone - + - ± + + 
Dydrogesterone - + - - ± - 
Progesterone derivatives      
Medroxyprogesterone 
acetate 
- + ± - - + 
Testosterone derivatives      
Norethisterone acetate + + + - - - 
Levonorgestrel - + + - - - 
Lynestrenol + + + - - - 
Spironolactone derivatives      
Drospirenone - + - + + - 
 
Route of administration 
Systemic HT can be administered through oral, transdermal, and vaginal 
routes. In addition, a levonorgestrel-containing intrauterine device enables 
intrauterine endometrial protection during combination therapy (Suvanto-
Luukkonen et al. 1998). In Finland, tablets for oral and patches and gel for 
transdermal treatments are available. A common daily dose of oral and 
transdermal gel E2 is 1-2 mg and 50-75 μg of transdermal patch E2. The 
vaginal route is used in Finland only for topical treatment of the mucosa and 
for that purpose tablets, rings, and creams are available. 
Orally administered estrogens are exposed to first-pass metabolism in the 
liver, unlike transdermally administered. Thus, orally administered estrogens 
increase sex hormone-binding globulin, corticosteroid-binding globulin, 
thyroxin-binding globulin, and angiotensinogen synthesis in the liver more 
effectively than transdermal estrogens (Kuhl 2005). Furthermore, orally and 
transdermally administered estrogens have showed different effects on some 
cardiovascular markers. Oral estrogen has positive effects on lipids 
increasing high-density lipoprotein and decreasing low-density lipoprotein, 
but negative effects in hemostasis, triglycerides, and inflammatory markers 
involved in atherosclerotic plaque (Barton 2013), whereas transdermal 
estrogen’s effect is neutral. Transdermal estrogen does not increase the risk 
of venous thromboembolism in contrast to oral estrogens (Olie et al. 2011). 
Knowledge of differences between progestogens administration routes is 
sparse. 
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Effects of postmenopausal hormone therapy 
Health-related quality of life 
Several major studies have been published regarding effects of HT on 
women’s HRQL, (Hlatky et al. 2002, Hays et al. 2003, Archer et al. 2005, Brunner 
et al. 2005, Welton et al. 2008) (Table 6). The results are inconclusive, and 
many of them lack an evaluation of hot flushes. For example, the Women’s 
Health Initiative trial (WHI) found no benefit of ET (Brunner et al. 2005)                                   
or of EPT (Hays et al. 2003) on HRQL. On the contrary, results of the Heart 
and Estrogen/Progestin Replacement Study (HERS) trial showed 
improvement in emotional measures of HRQL in women with vasomotor 
symptoms (Hlatky et al. 2002). The effects of HT on HRQL in women without 
hot flushes is controversial (Hlatky et al. 2002, Hays et al. 2003, Brunner et al. 
2005, Welton et al. 2008), and only one study showed some beneficial changes 
in sleep and sexual functioning after HT independent of the baseline hot 
flushes (Welton et al. 2008). 
 
Hormone therapy has  improved women’s sexual function and satisfaction 
(Welton et al. 2008, Gast et al. 2009) especially in symptomatic women within 
five years from menopause (Nastri et al. 2013). However, the WHI trial shows 
no benefit of HT on sexual functioning (Hays et al. 2003), although this 
finding is criticised because they addressed sexual functioning only with one 
question. Local ET improves sexual satisfaction and reduces vaginal dryness 
by improving the vaginal mucosa condition and thickness, lubrication, and 
sensation in vaginal tissues as the blood flow increases (Cayan et al. 2008). 
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Table 6. Impact of hormone therapy on Health related quality of life (HRQL) in previous studies. 
 
Study 
 
Study 
population 
Treatment Outcome 
measures 
Results 
 
Hlatky et al. 
2002 
HERS 
 
n=2763  
with CHD 
67 y 
 
 
3 years  
EPT (CEE 0.625 mg 
+MPA 2.5 mg) 
Placebo  
 
Rand-36 scales, 
Burnam scale 
 
-All women: physical functioning, 
mental health, energy ↓  
-Women with hot flushes: mental 
health ↑, depression scores ↓ 
Gambacciani 
et al. 2003 
n=50 
54 y 
12 weeks 
EPT (E2 1mg + 
NETA 0.5 mg) 
Controls: calcium 
WHQ  
Impact of hot 
flushes - 
Vasomotor and somatic 
symptoms,anxiety/fear, depressed 
mood, and poor sleep ↑ 
Hays et al. 
2003 
WHI 
 
n=1511 
63 y 
3 years 
EPT (CEE 0.625 mg 
+MPA 2.5 mg) 
Placebo 
Rand-36, 
WHI Insomnia 
Rating Scale,  
Burnam scale 
-at 1 year: physical function, bodily 
pain, sleep slightly ↑ 
-at 3 years: ↔  
-In 50-54 y group with hot flushes: 
vasomotor symptoms and sleep ↑ 
Brunner et 
al. 2005 
WHI 
n=1189 
63 y 
3 years 
ET (CEE 0.625 mg) 
Placebo 
Rand-36 
WHI Insomnia 
Rating Scale 
Burnam scale 
-at 1 year: sleep ↑ 
-at 3 years ↔ 
-In 50-54 y group with hot flushes 
HRQL ↔ 
Archer et al. 
2005 
 
n=845 
56 y  
 
13 months  
ET(E2 1 mg) 
EPT(E2+drospirenone 
1/2/3 mg) 
SF-36, 
WHQ 
Impact of hot 
flushes - 
-WHQ vasomotor symptoms and 
sleep ↑ 
-SF-36 scores ↔ 
Ylikangas et 
al. 2005 
 
n=208 
56 y 
9 years 
EPT (E2 2 mg +  
MPA 5 mg) 
Controls (n=771) 
15D 
Impact of hot 
flushes - 
HRQL ↑ after 6 and 9 years 
 
Welton et al. 
2008 
 
n=2130 
64 y 
1 year 
EPT (CEE 0.625 mg 
+MPA 2.5/5 mg) 
Placebo  
WHQ 
EuroQOL EQ-5D  
CES-D 
-WHQ vasomotor symptoms, sleep 
and sexual functioning ↑ 
-EuroQOL ↔ 
-sleep and sexual function ↑ in 
asymptomatic women 
Moriyama et 
al. 2008 
  
n=44 
54 y  
6 months 
-ET(E2 1 mg)/placebo 
-ET/placebo 
+physical exercise 
SF-36 
Kupperman 
Index 
-HRQL ↔ 
-vasomotor symptoms ↑ 
-SF-36 ↑ with physical exercise 
↑ = improvement, ↓= decline, or ↔ = neutral effect after hormone therapy 
Burnam scale = screening of depressive symptoms and disorders, CES-D = Centre for Epidemiological Studies 
depression scale, EuroQOL EQ-5D = European Quality of Life Instrument, Rand-36 = Rand 36-item Health Survey, 
SF-36 = Medical Outcome Study 36-item Short Form General Health Survey, 15D = 15-dimensional generic HRQL 
instrument, MPA = medroxyprogesterone acetate, NETA = norethisterone acetate, CHD = coronary heart disease, 
WHQ = Women’s Health Questionnaire 
 28 
Cardiovascular disease risk 
Estrogen has direct beneficial effects on the endothelial function. 
Estrogen vasodilates via endothelial nitric-oxide causing relaxation of 
smooth muscle in the vascular wall (Miller & Mulvagh 2007), most likely 
through ERα (Miller et al. 2008). Estrogen also promotes vasodilatation via 
prostacyclin (Ling et al. 2006), while estrogens effect on the vasoconstrictive 
and proaggregatory endothelin-1 secretion is neutral or even decreasing 
(Mikkola et al. 1998). However, EPT has shown contrary effects on the 
cardiovascular function (Koudy et al. 1994, Kuhl & Stevenson 2006, Sitruk-Ware 
2008); e.g., MPA stimulates coagulation and vasoconstriction in the vascular 
wall (Scarabin et al. 2011). These MPA effects have been suggested to 
contribute to the unfavorable cardiovascular effects of EPT (Kuhl 2005, Morin-
Papunen et al. 2008). 
A large number of observational and case-control studies (Grady et al. 
1992, Grodstein & Stampfer 1995, Grodstein et al. 2000) show approximately a 
30-50% lower risk of CVD in women using HT. The largest observational and 
still ongoing study is the Nurse’s Health Study (Grodstein 1996). This study, 
initiated in 1976, followed 70 533 women’s HT use, and by 2000 the data 
showed a 45% reduction of coronary heart disease risk in women using ET 
and a 36% reduction of risk in women using EPT. On the contrary, the risk of 
stroke was increased by 35% with ET and by 45% with EPT (Grodstein et al. 
2000).  
The observational studies have been criticised due to the “healthy woman 
effect”, meaning, for example, that women who originally chose to use HT 
might have been healthier than women who did not use HT. Thus, placebo-
controlled prevention studies were initiated. The first randomised controlled 
study on HT was a secondary prevention trial of coronary heart disease, the 
HERS, in older women with established coronary heart disease. This study 
associated EPT with more coronary events, particularly during the first 
months of the treatment (Hulley et al. 1998, Grady et al. 2002a). Later, the 
ESPRIT (Cherry et al. 2002) trial studying ET, and several other studies of 
EPT on secondary prevention (Waters et al. 2002, Hodis et al. 2003, Lakoski et 
al. 2005, Collins et al. 2006) failed to demonstrate HT’s cardioprotection.  
Due to the previous controversial results, a primary prevention trial, the 
WHI, was initiated in 1992 to assess the risk-benefit profile of HT (ET and 
EPT) on the risk of chronic diseases. In 2002 after an average of 5.2 years 
follow-up, the EPT arm was discontinued due to an increase in coronary 
events with active treatment (Rossouw et al. 2002). In 2004, the ET arm was 
also terminated one year earlier than planned. It showed increased risks for 
stroke and venous thromboembolism, while the effect on coronary heart 
disease was neutral (Anderson et al. 2004). Re-analyses of the WHI-data 
according to age groups showed that ET reduced the risk of coronary heart 
events in the age group 50 to 59 years, and the effect was neutral in older age 
groups (Hsia et al. 2006) as well as in all age groups with EPT (Rossouw et al. 
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2007, Rossouw et al. 2013). The latest analyses of WHI’s results including an 
extended post-intervention follow-up (median 8.2 years) conclude that the 
overall risk of coronary heart disease was not significantly increased after 
EPT and slightly decreased after ET (Manson et al. 2014).  
The primary prevention nature of the WHI trial can be criticised (Mikkola 
& Ylikorkala 2005, Tuomikoski & Mikkola 2014), since women with a history of a 
CVD event, such as myocardial infarction, stroke, or transient ischemic 
attack, were not excluded from the trial. Moreover, the participants’ mean 
age was 63 years, and hypertension, smoking, hypercholesterolemia, and 
diabetes were common in the study population. A woman’s age and time 
since menopause are likely to influence the outcomes of HT (Bassuk & 
Manson 2014, Gurney et al. 2014). This supports the “timing hypothesis”, 
which suggests that the cardiovascular effects of HT are dependent on the 
individual’s vascular health at the time of initiation (Mikkola & Clarkson 2002, 
Clarkson et al. 2013). Therefore, new data about HT effects in healthy, recently 
menopausal women is required. 
 The length of follow-up, different treatment regimens in terms of ET 
versus EPT, and moreover possible adverse effects of MPA have been 
suggested to explain the divergent results between observational studies and 
randomised controlled trials (Harman 2014). More importantly, women in the 
WHI were practically asymptomatic regarding hot flushes, whereas 
participants of the observational studies were younger and entered the 
studies specifically to treat their hot flushes. Thus, future research on 
women’s cardiovascular health should consider the role of hot flushes (van 
der Schouw & Grobbee 2005, Tuomikoski et al. 2011). 
Effects on other organs 
Estrogen sustains bone structure and restores bone mineral density, thus 
HT reduces osteoporotic fractures by 40-59% (Farquhar et al. 2009, Santen et 
al. 2010). Combination therapy reduces the risk of colorectal cancer 
(Marjoribanks et al. 2012), but the effect of ET remains contradictory and is 
most likely neutral (Santen et al. 2010). Progestins in HT protect the 
endometrium from estrogen’s proliferative effect, thus EPT reduces the risk 
of endometrial cancer (Brinton & Felix 2014). The risk of endometrial cancer 
is even lower with continuous combined EPT than in women not using HT 
(Jaakkola et al. 2009, Santen et al. 2010, Jaakkola et al. 2011).  
An increased breast cancer risk is the most feared side effect of HT. The 
current understanding is that EPT increases breast cancer risk (Lyytinen et al. 
2009, Rossouw et al. 2013). Data on ET is not uniform: latest analysis of the 
WHI trial shows ET to lower breast cancer risk (Manson et al. 2014), whereas a 
large Finnish cohort study (Lyytinen et al. 2006) and statements (Santen et al. 
2010, Marjoribanks et al. 2012, Santen 2014) conclude that the risk is increased 
after 5 years of ET use or even earlier.  
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It is well demonstrated that oral HT increases the risk of venous 
thromboembolism ca. 2-fold (Olie et al. 2011), the risk being highest during 
the first year of use (Miller et al. 2002). There is some evidence that EPT 
would increase the risk more than ET (Smith et al. 2004, Sare et al. 2008), but 
the mechanisms are unclear. A recent observational study associated the use 
of oral CEE with a greater risk of venous thromboembolism than oral E2 use 
(Smith et al. 2014). 
Several observational and follow-up studies indicate that HT reduces the 
risk of all-cause dementia and Alzheimer’s disease (Barrett-Connor & Laughlin 
2009, O'Brien et al. 2014). However, more recent placebo-controlled studies 
have yielded inconclusive results.  Studies on ET show a neutral impact on 
memory (Shumaker et al. 2004, Resnick et al. 2009). On the other hand, in 
postmenopausal women older than 65 years, HT does not appear to improve 
memory, and EPT may even be harmful (Binder et al. 2001, Grady et al. 2002b, 
Shumaker et al. 2003, Resnick et al. 2006). The “timing hypothesis” of HT 
initiation might also be important regarding memory and cognition (Barrett-
Connor & Laughlin 2009, Fischer et al. 2014), especially vascular dementia 
(Henderson 2014). Moreover, hot flushes have not been evaluated in the 
memory and cognition studies.  
Estrogens possess neurotrophic and neuroprotective effects on the central 
nervous system (Resnick et al. 2006, Henderson 2014). In contrast, MPA has 
showed negative impacts and attenuation of estrogen-induced 
neuroprotection in the brain (Nilsen & Brinton 2002, Liu et al. 2010, Irwin et al. 
2011). Estrogen also affects the autonomic nervous system’s tone in the brain 
controlling sleep, heart rate, and body temperature (Mohamed et al. 1999, 
Saleh & Connell 2007, Miller et al. 2008).   
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Cardiovascular autonomic nervous system 
The cardiovascular autonomic nervous system maintains the circulatory 
balance of the body. It holds a basal tone and a balance between the 
sympathetic and parasympathetic divisions and can be additionally 
stimulated by means of changes in, e.g., position or physical activity. For 
example, when standing up from a supine position, autonomic reflexes 
change the blood pressure and heart rate (HR) to maintain sufficient 
circulation in the brain. The sympathetic nervous system is responsible for 
energy production and general activity of the body and enables the fight or 
flight –response when necessary. The parasympathetic nervous system is 
dominant when immediate reactions are unnecessary, known as rest and 
digest –response, guiding the balance of the body towards a resting tone. The 
sympathetic nervous system and the parasympathetic nervous system 
typically function reciprocally. However, during rapid circulatory 
adaptations, they rather complement each other to maintain the 
homeostasis. The hypothalamus is the most important coordinating center of 
the autonomic regulation, but respiratory, cardiac, and vascular regulation 
centers are located in the brain stem (pons and medulla) (Figure 1).  
 
Figure 1. Cardiac, respiratory, and thermoregulatory control centers located in the brain stem. 
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The function and responses of the autonomic nervous system are mainly 
based on reflex arcs: input from visceral mechano- and chemosensory or 
thermal receptors travels by afferent pathways to the central nervous system, 
where the information is modulated and transmitted to the effector organ 
through the efferent pathways (Figure 2).  The efferent autonomic pathways 
consist of preganglionic and postganglionic neurons with synapses in 
autonomic ganglia. The postganglionic neurons innervate the effector organs. 
 
 
Figure 2. Efferent autonomic innervation of heart and blood vessels. Printed with permission 
from Professor Richard Klabunde, PhD, cvpphysiology.com. 
Blood pressure 
The sympathetic nervous system regulates the vascular tone of all blood 
vessels (Figure 2), except small arterioles and venules, mainly via receptors 
located in the smooth muscle layer of the vascular wall. However, blood 
vessels lack parasympathetic innervation, except for cranial, visceral and 
genitourinary vessels. By affecting peripheral resistance, the sympathetic 
nervous system regulates arterial blood flow and blood pressure of all organs; 
by vasoconstriction and vasodilatation, it balances the amount of blood 
between the venous capacitance vessels and active circulation. 
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Both the sympathetic and parasympathetic nervous systems act as major 
short-term regulators of the systemic blood pressure maintaining stable 
mean arterial pressure throughout the body. The baroreceptors, located 
within the wall of the carotid sinuses and in the wall of the aortic arch, react 
to stretch in the vessel wall following pressure changes, and this information 
is mediated to the central nervous system. Elevation of blood pressure leads 
rapidly to parasympathetic excitation and sympathetic inhibition, which 
reduces HR, cardiac output, and peripheral resistance lowering the systemic 
blood pressure. When blood pressure drops suddenly, for example after 
standing up, opposite changes occur. This is defined as the arterial baroreflex 
(Sunagawa et al. 2001, Vongpatanasin 2009) (Figure 3). 
 
 
 
 
 
 
Figure 3. The arterial baroreceptor reflex. 
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Heart rate 
The sinus node (sinoatrial node) is located in the right atrium and acts as 
the heart’s pacemaker. Sympathetic stimulation increases the firing rate of 
the sinus node. Parasympathetic stimulation acts vice versa, but has a 
stronger influence on the sinus node than sympathetic stimulation. Thus, the 
resting HR is mainly under parasympathetic control, meaning that a 
withdrawal of parasympathetic stimulation increases HR (Haapalahti et al. 
2000). The parasympathetic activity to the heart is mediated by the vagus 
nerve and therefore is often referred to as “vagal” control of the heart 
(Hildreth et al. 2009) (Figure 2).  
The heart rate constantly varies from beat-to-beat and is influenced by 
respiration, blood pressure and thermal conditions under autonomic 
regulation (Perini & Veicsteinas 2003). This is defined as heart rate variability 
(HRV). The component of HR that is in phase with the respiration frequency 
is defined as respiratory sinus arrhythmia (Sin et al. 2010).  The heart rate 
accelerates during inspiration and decelerates during expiration. The 
respiratory sinus arrhythmia is dependent upon both respiratory rate and 
depth (i.e. tidal volume). The information of respiratory sinus arrhythmia 
accumulates from arterial baroreceptors, low-pressure receptors in the heart, 
and stretch receptors in the lungs, the vagus nerve mediates the impulses 
from the central autonomic nuclei peripherally (Wheeler & Watkins 1973). It 
reflects cardiac parasympathetic control of HR via sinus node (Grossman & 
Taylor 2007, Haapalahti et al. 2006). 
Modulators of cardiovascular autonomic function 
Tonic parasympathetic activity is higher in women than in men (Huikuri et 
al. 1996, Sinnreich et al. 1998), but this difference diminishes along with aging 
(Fagard et al. 1999). Women have a higher resting HR (Fagard et al. 1999, 
Gerritsen et al. 2003) and attenuated arterial baroreflex responsiveness 
(Huikuri et al. 1996) compared with men. Sympathetic activity increases with 
age (Seals & Esler 2000), when the cardiovascular autonomic nervous system’s 
regulation capacity declines. Common consequences are elevated blood 
pressure and orthostatic hypotension; the former associates with increased 
peripheral vascular resistance due to increased sympathetic activation and 
the latter with decreased sensitivity of the baroreceptors. Hypertension in the 
elderly, however, is attributed mainly to increased arterial stiffness and 
structural narrowing of small arteries. It is well demonstrated that especially 
HR responses to physiological stimuli (Baldwa & Ewing 1977, Piha 1991, 
Fagard et al. 1999) and parasympathetic regulation (Saeki et al. 1998, Umetani 
et al. 1998, Fagard et al. 1999, Vallejo et al. 2005) decrease with age.  
Sleep is characterised by rapid fluctuations in autonomic activity in a 
complex manner during the different sleep stages (Ako et al. 2003, Virtanen et 
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al. 2008). Parasympathetic activity dominates during non-REM sleep and 
sympathetic activity dominates during REM sleep (Versace et al. 2003).  
Diminished HRV associates with both low body mass index (<19 kg/m2) 
(Cifkova et al. 2008, Mazurak et al. 2011), and obesity (≥30kg/m2) (Quilliot et al. 
2001, Cifkova et al. 2008, Sztajzel et al. 2009). However, strong evidence 
suggests that obesity and metabolic syndrome are generally accompanied 
with sympathetic overdrive (Grassi et al. 2004, Grassi 2006, Lambert et al. 
2010). Stress is also associated with activation of the sympathetic nervous 
system (Kajantie & Phillips 2006). 
Physical activity and endurance training enhance cardiovascular 
autonomic function seen as an increased resting HRV (Middleton & De Vito 
2005), whereas in several diseases impairment is seen as a decresed HRV: 
diabetes (Bagherzadeh et al. 2013), hypothyroidism (Celik et al. 2011), and 
neurological conditions, e.g., Parkinson’s disease and epilepsy, as well as 
alcohol abuse. Depression also relates to a higher resting HR and lower HRV 
(Carney et al. 2005), which in turn has been linked to increased risk of CVD 
(Pizzi et al. 2008, Taylor 2010). 
Autonomic function and cardiovascular disease risk 
Heart rate and HRV reflect CVD risk and outcome. Greater cardiovascular 
reactivity and sympathetic activity in response to stress are related to 
worsened cardiovascular risk (Chida & Steptoe 2010, Chumaeva et al. 2010, 
Fuller-Rowell et al. 2013). High resting HR relates to all-cause mortality, death 
from CVD, and sudden cardiac death (Habib 1999, Thayer & Lane 2007). 
Reduced HRV in post-myocardial infarction patients is associated with 
mortality (Kleiger et al. 1987). More specifically, lowered vagal function has 
related with all-cause mortality (Tsuji et al. 1994, Thayer et al. 2010) and both 
sudden and non-sudden death after acute myocardial infarction (Huikuri & 
Stein 2012). Decreased HRV has been also associated with the development of 
myocardial infarction (Tsuji et al. 1996), recurrence of myocardial infarction 
(Task force 1996), arterial hypertension (Singh et al. 1998, Schroeder et al. 2003, 
Thayer & Lane 2007, Erdogan et al. 2011), diabetic autonomic neuropathy (Task 
force 1996), progression of atherosclerosis (Huikuri et al. 1999), heart failure 
(La Rovere et al. 2003), and ischemic and idiopathic cardiomyopathy (Rashba 
et al. 2006). Depressed baroreflex sensitivity is related to ischemic heart 
disease and heart failure, hypertension, renal failure (La Rovere et al. 2011), 
and cerebral stroke (Robinson et al. 2003). In addition, altered autonomic 
nervous function is suggested to play a role in hypertension and e.g. angina 
(Lucini et al. 2002, Christou et al. 2005, Joyner et al. 2008). 
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Autonomic function and menopause 
Findings on the effect of menopause on blood pressure are divergent. 
Blood pressure, both resting and responsive to activity, is thought to increase 
more steeply around the menopause (Vongpatanasin 2009). Several theories 
on the menopause-related elevation of blood pressure exist. According to one 
theory, vasodilatation is dominant in young women, resulting in low blood 
pressure levels, and with aging, sympathetic nervous activity rises, and the 
vasodilatory effect is lost (Hart et al. 2012). Plasma noradrenalin levels are 
also elevated in postmenopausal women compared with premenopausal 
women (Sherwood et al. 2010), reflecting vasoconstriction. Another theory 
suggests that the alteration in central autonomic regulation together with 
enhanced vascular adrenergic sensitivity cause the elevation of blood 
pressure in postmenopausal women (Vongpatanasin 2009). However, the role 
of sex steroid hormones and menopausal symptoms in the blood pressure 
regulation remain unclear. 
The balance of the cardiovascular autonomic function shifts towards 
sympathetic dominance with advancing age, but the role of menopause is 
unclear (Lavi et al. 2007). Some studies have shown signs of decreased HRV 
(Monda et al. 2006) and increased sympathetic activity in postmenopausal 
women compared with premenopausal women: augmentation of muscle 
sympathetic nerve activity (Narkiewicz et al. 2005), higher resting HR, and 
more increase in sympathetic activity in response to stress (Farag et al. 2003). 
Yet, the results are not uniform (Day et al. 2011) and some clinical and 
experimental evidence suggests that advancing age rather than menopause 
itself explains these findings (Tezini et al. 2013). Estrogen affects autonomic 
tone, seen clearly as attenuated HRV after a sudden decrease of estrogen due 
to surgical menopause (Mercuro et al. 2000). The effect of slowly depleting and 
fluctuating estrogen levels during the physiological menopause remain 
unclear and demands further research. 
 
 
 
 
 
 
 37 
Autonomic function and hormone therapy 
Estrogen with (Beljic et al. 1999, Gautam et al. 2011) or without progestogen 
(Christ et al. 2002, De Meersman et al. 1998, Vongpatanasin et al. 2001) has 
lowered blood pressure in short-term (De Meersman et al. 1998, Beljic et al. 
1999, Gautam et al. 2011) and ambulatory measurements (Vongpatanasin et al. 
2001, Christ et al. 2002). Hormone therapy lowers HR (Rosano et al. 1997, Beljic 
et al. 1999) and increases HRV in some (Yildirir et al. 2001, Gautam et al. 2011), 
but not all studies (Lipsitz et al. 1995, Hunt et al. 2001, Niskanen et al. 2002, 
Carnethon et al. 2003) ( Table 7). The conflicting results could be at least in 
part explained with varying methodologies and different HT regimens. For 
example, EPT has attenuated the positive effects of estrogen-only therapy 
(Christ et al. 2002). Of the three placebo-controlled studies, one showed 
reduced HR response to isometric muscle contraction (handgrip test) but no 
effect on resting HR after ET (De Meersman et al. 1998). Another study 
detected no differences in HR or blood pressure responses between ET, EPT 
or placebo groups during a psychologically stressful task (Farag 2002). 
Furthermore, transdermal E2 has also been shown to decrease sympathetic 
nerve discharge and resting HR (Vongpatanasin et al. 2001). Only one previous 
study associated flushing with a more prominent decrease in HR and systolic 
blood pressure after EPT (Beljic et al. 1999). Taken together, the previous 
studies show some positive effects of HT, but data are insufficient regarding 
HT in relation to cardiovascular autonomic function and pre-treatment hot 
flush status. Hormone therapy’s effects on cardiovascular autonomic 
responses are especially poorly understood. 
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Assessment of cardiovascular autonomic function 
Measurements of cardiovascular autonomic function in controlled 
laboratory conditions quantify resting levels and responses of blood pressure, 
HR, and HRV to specific maneuvers challenging the autonomic nervous 
system. The clinical responses always reflect the balance of sympathetic and 
parasympathetic systems and their reciprocal reactions. The main features of 
the cardiovascular autonomic function tests in a short-term setting are 
presented in Table 8. 
Heart rate variability, expressing beat-to-beat fluctuation in sinus rhythm, 
can be measured as a function of time (time domain), frequency (frequency 
domain), or with non-linear methods (Kleiger et al. 2005, Lombardi & Stein 
2011), all evaluating the contribution of parasympathetic and sympathetic 
control (Task force 1996). The time domain and non-linear measurements are 
recommended for ambulatory long-term recordings, whereas frequency 
domain analyses are recommended for controlled short-term recordings 
(Task force 1996, Tahvanainen et al. 2012).  
Time domain indexes of HRV measure the dispersion of individual R-R 
intervals around their mean (Zaza & Lombardi 2001). The square root of the 
mean of the sum of the squares of differences between adjacent normal-to-
normal R-R intervals (RMSSD) and the coefficient of variation of R-R 
intervals (CoV=SD/mean x 100, proportioning HRV to HR), and the 
percentage fraction of consecutive R-R intervals that differ by more than 50 
milliseconds (pNN50) express the time domain HRV in short-term 
measurements (Task force 1996). 
Heart rate variability oscillates at different frequencies. The purpose of 
the frequency domain analysis of HRV (power spectral density analysis) is to 
describe the distribution of variance as a function of frequency, thereby 
enabling recognition of sympathetic and parasympathetic regulation. The 
HRV power spectrum has three major components; high (HF), low (LF), and 
very low (VLF) frequency bands, which are quantified by measuring the areas 
under the curve (VLF ≤0.04 Hz, LF 0.04–0.15 Hz, HF 0.15–0.40 Hz) (Figure 
5). The LF power associates with oscillations of arterial pressure (considered 
mainly as a marker of sympathetic modulation), and HF power is dependent 
on respiratory sinus arrhythmia (considered to be a marker of 
parasympathetic modulation). Both LF and HF can be reported in absolute 
(power) and normalised (relative to total power as a sum of LF and HF) 
values nLF and nHF. The LF/HF ratio is an established indicator of 
sympathetic-parasympathetic balance (Malliani et al. 1991, Lombardi & Stein 
2011). The VLF is not clearly attributed to a specific neural component, but 
associates rather with thermoregulatory rhythms, the renin-angiotensin 
(Taylor et al. 1998) or with peripheral vasomotor regulation (Perini & 
Veicsteinas 2003). In short-term measurements, HRV should be controlled  
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for respiration, since they are strongly linked. Therefore, HRV is usually 
quantified during controlled breathing timed at a certain frequency (Figures 
4 and 5). 
 
 
 
 
 
Figure 4. Tachogram of the controlled breathing test. RRI= R-R interval 
 
 
 
 
  
Figure 5.  An example of the power spectrum distribution of heart rate variability during controlled 
breathing test produced by spectral analysis of the tachogram in Figure 4. The respiration-related 
and dominant high frequency (HF) component at 0.25 Hz corresponding to the controlled 
breathing frequency of 15/min is clearly identified. 
LF = power in low frequency band (0.04–0.15 Hz)   
HF = power in high frequency band (0.15–0.4 Hz)    
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Deep breathing 
The most specific and most often utilised test of parasympathetic function 
is the deep breathing test, since respiratory sinus arrhythmia is dependent on 
the parasympathetic branch of the cardiovascular autonomic nervous system. 
When the subject breathes cued slowly and deeply using subjective maximal 
vital capacity, the difference between maximum and minimum HRs is 
calculated from concomitant electrocardiogram. This is known as “the deep 
breathing difference” reflecting the magnitude of the respiratory sinus 
arrhythmia (Wheeler & Watkins 1973).  
Valsalva manoeuvre 
The Valsalva manoeuvre causes dynamic variations of HR and blood 
pressure due to changes in intra-thoracic pressure. The Valsalva manoeuvre 
is carried out by blowing against resistance, which elevates the intra-thoracic 
pressure reducing the venous return to the heart. The responses of HR and 
blood pressure are mediated by the baroreflex (Baldwa & Ewing 1977). 
Orthostatic test 
Posture change from supine to standing causes blood to pool in the 
capacitance vessels of the trunk and lower extremities. Baroreceptors react to 
the loss of central blood volume, and the arterial baroreflex induces a rapid 
parasympathetic withdrawal and a sympathetic activation within a few 
seconds (Thulesius 1976). This results in rapid HR acceleration (20-25%), 
improvement in cardiac contractility and elevation of the peripheral vascular 
resistance. As a result, systolic blood pressure remains almost unchanged 
during standing. 
Handgrip test 
The sympathetic function can specifically be tested with isometric muscle 
exercise, such as the handgrip test, where isometric muscular contraction 
causes generalised sympathetic activation to the heart and blood vessels. 
Usually, a dynamometer is squeezed for 3 minutes, and HR and blood 
pressure responses are measured during the exercise (Ewing et al. 1974). In 
the beginning, the HR accelerates due to parasympathetic withdrawal and 
later due to sympathetic activation (Martin et al. 1974).   
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AIMS OF THE STUDY 
This thesis was designed to investigate the impact of hot flushes on the 
health-related quality of life and cardiovascular autonomic nervous function 
in recently postmenopausal women before and during various forms of 
hormone therapy. Moreover, it was elucidated whether there is a relation 
between premenstrual symptoms and menopausal complaints. 
 
The specific aims of the studies were to evaluate: 
 
 
? Health-related quality of life in women with or without hot flushes 
before and during  postmenopausal hormone therapy (Study I) 
 
? The association between premenstrual symptoms and 
postmenopausal hot flushes affecting health-related quality of life 
(Study II) 
 
? Impact of hot flushes on the cardiovascular autonomic responsiveness 
(Study III) 
 
? The effect of postmenopausal hormone therapy on cardiovascular 
autonomic responsiveness in women with and without hot flushes 
(Study IV) 
 
? The effect of hot flushes and postmenopausal hormone therapy on 
heart rate variability (Study V) 
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SUBJECTS AND STUDY DESIGN 
The women for this study were recruited via local newspaper 
advertisements in 2005-2006. First, a trained research nurse interviewed all 
1500 willing responders over the telephone.  Second, the 400 women who 
met the inclusion criteria (age 48-55 years, time since last menstrual period 
6-36 months, no previous HT use) recorded their vasomotor symptoms for 
two weeks with a structured questionnaire that defined the severity and 
number of the symptoms (Panay et al. 2007). Finally, after further exclusion 
criteria (chronic illnesses or use of regular medication, smoking, level of FSH 
<30 IU/l, body mass index >30 kg/m2, previous hysterectomy or 
ovariectomy and inability to comply with the study plan) and rating the 
vasomotor symptoms, a total of 150 women were eligible for this study 
(Figure 6) (Tuomikoski et al. 2009a, Tuomikoski et al. 2009b). 
In the hot flush diary, vasomotor symptoms were defined as absent if 
there were no sensations of heat at all, mild if there was only a slight 
sensation of heat without sweating, moderate if there was an intense 
sensation of heat and some perspiration while being awake, and severe with 
profuse sweating and the hot flush clearly interfering with daily life or sleep. 
To obtain an overall picture of vasomotor hot flushes, mild symptoms were 
scored 1, moderate symptoms 2 and severe symptoms 3, and furthermore, 
the HFWWS score was calculated as the sum of all weighted symptoms 
during one week (Notelovitz et al. 2000, Sloan et al. 2001) (Table 9). The 
participants showed great variation in hot flushes at baseline (0–298 in 
HFWWS score) and were divided into four subgroups according to the 
scores: 23 women reported no hot flushes, 34 mild flushes (HFWWS 0.5–
9.5), 30 moderate flushes (HFWWS 10–99.5) and 63 severe flushes 
(HFWWS ≥100). In order to accurately evaluate the significance of hot 
flushes in our study, we excluded women with intermediate hot flushes, i.e. 
>3 mild hot flushes to <7 moderate to severe hot flushes/day. 
 
Table 9. Classification of hot flushes. 
 
Hot flushes Definition Score HFWWS 
= amount of scored 
symptoms during one week 
None No hot flushes 0 0 
Mild Slight sensation of heath without sweating 1 0.5-9.5 
Moderate An intense sensation of heat with some 
perspiration while being awake 
2 10.0-99.5 
Severe An intense sensation of heat with profuse 
perspiration that interferes with daily life or sleep 
3 ≥100.0 
HFWWS = Hot Flush Weekly Weighted Symptom score  
An example: A woman experiences 22 mild, 30 moderate and 6 severe hot flushes during two weeks. 
HFWWS = (22x1 + 30x2 + 6x3)/2 = 100/2 = 50 
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Figure 6. Study protocol for studies II and III. 
 
 
 
In studies II and III, women were classified as asymptomatic, or having 
mild, moderate or severe hot flushes according to the HFWWS (Figure 6, 
Table 9). For the randomised controlled studies I, IV, and V women with ≥7 
moderate or severe hot flushes/day were classified as “women with hot 
flushes” and women reporting only ≤3 mild hot flushes/day or no hot flushes 
at all were classified as “women without hot flushes”.  
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For the HT trial, the women were randomised in blocks of four according 
to the hot flush status at baseline. They were treated either with transdermal 
E2 hemihydrate gel 1 mg/day, oral E2 valerate 2 mg/day alone or combined 
with MPA 5 mg/day or with placebo for six months with a double-blind and 
double-dummy technique (Figure 7). After a careful comparison of treatment 
effects, we did not find differences between oral and transdermal E2. 
Therefore, to better compare the effects of unopposed E2 to E2 with MPA, 
oral and transdermal groups were combined into a sole E2 group (ET) in 
Study IV.  In studies I and V all treatments showed comparable effects and 
were therefore combined into a single HT group for further comparisons. 
 
 
 
 
 
 
 
Figure 7. The study protocol for hormone therapy studies I, IV, and V. 
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The treatment regimens were provided by Orion Pharma Oyj (Espoo, 
Finland). To guarantee the double-dummy technique of the trial, all women 
used both tablets (active or placebo) and gel (active or placebo) which was 
packed separately as daily doses. Compliance was evaluated by counting the 
returned unused packages and tablets. Endometrial thickness was evaluated 
at baseline and at three and six months’ clinical visits. As a precaution 
women, were treated with MPA 5 mg/day for two weeks after the study 
protocol if endometrial thickness was ≥ 9 mm.  
To further study the relationship between premenstrual symptoms and 
postmenopausal hot flushes, a questionnaire was sent by mail to the same 
study population described above in April 2012. This questionnaire included 
PSST and additional questions about age at possible manifestation of 
premenstrual symptoms, menstrual cycle and occurrence of depression or 
other mental disorders. Of the 150 women, 120 (80%) returned the 
questionnaire and were further interviewed over the telephone by a research 
nurse to confirm their answers. 
Of the 150 women included in the trial, 138 (92%) completed the study 
protocol and underwent cardiovascular autonomic testing at 6 months 
(Studies IV and V). Twelve women discontinued the trial (7 withdrew 
consent, 3 were lost during follow up, 2 discontinued due to spotting), and 
these women were evenly distributed between the different treatment 
groups. In addition, in the HRQL part of the trial (Study I), nine women’s 
data collection was incomplete. Hereby, 132 women (68 with hot flushes and 
64 without) were eligible for HRQL data analysis. Therefore, the missing data 
were replaced and analysed according to intention to treat –principle with 
linear interpolation. In Study II, data from 120 women were available for 
analyses.  
This study was approved by the Helsinki University Women’s Hospital 
Ethics Committee, and registered in the National Agency for Medicine 
(EudraCT 2004–005091–16) and the U.S. National Institutes of Health 
Clinical Registry (No. NCT00668603). Written informed consent was 
obtained from all participants and the study was conducted according to the 
principles of Good Clinical Practice and the Declaration of Helsinki. 
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Cardiovascular autonomic function in relation to 
premenstrual and vasomotor symptoms 
To further study those women that tend to have strong symptoms in their 
fertile age and also later on at menopause, we compared the cardiovascular 
autonomic responses of women having both severe premenstrual and 
postmenopausal vasomotor symptoms (PSST score ≥15, HFWWS ≥100) with 
women having only mild or no symptoms at all (PSST score ≤3, HFWWS 
≤9.5). Furthermore, to find out whether previous premenstrual symptoms 
would be an independent determinant in the autonomic regulation in 
menopause, we compared women having both severe premenstrual and 
vasomotor symptoms (PSST score ≥15, HFWWS ≥100) with women having 
severe vasomotor symptoms but only mild premenstrual symptoms (PSST 
score ≤3, HFWWS ≥100). 
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METHODS 
Women’s Health Questionnaire 
We measured the HRQL with the WHQ, which is a reliable and well-
documented tool to assess a wide range of physical and emotional symptoms 
and possible health changes in middle-aged women (Hunter 1992, Hunter 
2000, Zöllner et al. 2005). It is a self-administered questionnaire composed of 
36 items capturing 9 domains of women’s health: vasomotor symptoms (two 
items), somatic symptoms (seven items), anxiety and fears (four items), 
depression (seven items), sleep problems (three items), sexual behavior 
(three items), memory and concentration (three items), menstrual cycle-
related symptoms (four items) and attractiveness (two items) (Appendix A). 
Each item is answered on a four-point scale (1-4) and then reduced to a 
binary scale (1 and 2=0, 3 and 4=1) for scoring. A mean score (between 0 and 
1) is calculated for each domain (of the corresponding items), and thus the 
higher the score, the better the quality of life. 
General health and menopausal symptoms 
The women evaluated their general health by a VAS (range from 0 to 
100), higher score indicating better health. In one question, women 
compared their current health state with the average of past 12 months (scale 
1= worse, 2=about the same, 3=better) (Appendix C). Menopausal symptoms 
concerning the past two weeks were assessed with a modified Kupperman 
Index (Kupperman et al. 1953) comprised of 19 items answered on a four-point 
scale regarding the frequency of the symptoms (Appendix B). 
 
 
 
Sexual wellbeing 
Sexual wellbeing was assessed with a modified MFSQ (McCoy & Davidson 
1985, Wiklund et al. 1993), where the woman’s sexual experience during the 
past four weeks is asked by a self-report questionnaire. The MFSQ provides 
an overall score and three subscales denoting sexual problems (two items), 
sexual satisfaction (five items) and satisfaction with the partner (three 
items). Each item consists of seven-point Likert-scales, higher score indicates 
better sexual satisfaction, except for the sexual problems subscale (Appendix 
D). 
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Premenstrual symptoms screening tool 
The prevalence and severity of premenstrual symptoms were evaluated 
with the PSST consisting of 19 items (Appendix E) (Steiner et al. 2003). The 
first 14 items assess specific premenstrual symptoms, and 5 additional items 
evaluate the impairment of work efficiency, taking note of home 
responsibilities, social activities or relationships because of premenstrual 
symptoms. All items have a severity rating (not at all, mild, moderate and 
severe). We calculated the PSST score as the sum of all items rated on a four-
point scale (0-3 points), reflecting the severity of premenstrual symptoms. 
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Cardiovascular autonomic function tests 
The participants underwent a series of cardiovascular autonomic function 
tests at baseline (Study III) and after 6 months of HT (studies IV and V) in 
the following order: 
 
1. Controlled breathing. A 5-minute baseline recording while 
breathing quietly at 15 cycles/minute. 
2. Deep breathing. Six breathing cycles (inspiration + expiration) at 
maximal tidal volume in one minute. 
 
3. Active orthostatic test. The women stood up quickly from a supine 
position and remained standing still for 8 minutes. Blood pressure 
was measured at 0.5, 1, 3, 5 and 8 minutes.  
 
4. Valsalva manoeuvre. After maximal inspiration, forced expiration 
against a resistor with airway pressure of 40 mmHg was maintained 
for 15 seconds. 
5. Sustained handgrip. The women squeezed a dynamometer at 30% 
of predetermined maximal handgrip strength for 3 minutes. Blood 
pressure was measured at rest and at 1, 2 and 3 minutes. 
 
Experienced staff carried out the measurements in the forenoon in an 
undisturbed environment. The testing room was specifically designed for 
clinical cardiovascular experiments: quiet, dim, and a stable temperature at 
24 °C. 
The women were instructed to refrain from alcohol for 36 hours and 
caffeinated beverages for 6 hours before testing. Prior to testing, all women 
had 10 minutes of supine rest.  Additionally, a 5-minute minimum rest before 
each test allowed the stabilisation of the basic physiologic state and was 
followed by a 5-minute baseline recording. Blood pressure was measured 
manually with a calibrated sphygmomanometer. The heart rate was 
monitored continuously with standard 12-lead electrocardiography during all 
tests, and the signals were digitised at 200 Hz (WinAcq, Absolute Aliens Co., 
Turku, Finland). 
Heart rate responses to the autonomic tests were reviewed blind to the 
hot flush status with biosignal analysis software (WinCPRS version 1.3, 
Absolute Aliens Co., Turku, Finland) by an experienced physiologist. 
Automatic R-wave detection was followed by manual editing of data with 
linear interpolation to exclude occasional ectopic beats or occasional 
artefacts. Inadequate Valsalva manoeuvres (expiration pressure less than 40 
mmHg, duration less than 15 seconds) and handgrip tests (duration less than 
3 minutes) were also excluded from further analyses. Mean, minimum 
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(corresponding to maximum HR) and maximum (corresponding to 
minimum HR) R-R intervals during the tests were identified. Maximum 
changes of HR and blood pressure from baseline were calculated.  
The HR responses in the autonomic tests were further quantified by using 
standard calculated indices (Table 10).   
Heart rate variability in the time domain was assessed during controlled 
and deep breathing and the active orthostatic test by calculating the RMSSD 
and CoV of R-R intervals.   
Heart rate variability in the frequency domain was assessed during 
controlled breathing and the active orthostatic test by computing the spectral 
variation of R-R intervals using a fast Fourier transform (Task force 1996). 
Power spectra were further quantified by measuring the power in the VLF, 
LF, and HF frequency bands and by calculating the LF/HF ratio. 
 
 
 
Table 10. Definitions of variables derived from cardiovascular autonomic tests. 
 
Variable Definition 
Deep breathing difference1: 
E-I 
 
 
E-I(b) 
 
maximum R-R interval during expiration – minimum R-R interval during 
inspiration (ms) 
 
minimum heart rate during expiration – maximum heart rate during 
inspiration (beats/min) 
 
30/15 –ratio2 
(Active orthostatic test) 
 
Valsalva ratio3 
(Valsalva manoeuvre) 
 
Tachycardia ratio4 
(Valsalva manoeuvre) 
 
 
 
1 (Wheeler & Watkins 1973)                                 
2 (Ewing & Clarke 1978)                                 
3 (Levin 1966)                                 
4 (Baldwa & Ewing 1977)                                 
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Statistical analyses 
Power analysis was made on the primary outcome measure, i.e. 
differences between women with and without hot flushes in the responses to 
HT in pulse wave analysis (Tuomikoski et al. 2009a), and responses in the 
HRQL and cardiovascular autonomic function tests were secondary end-
points of this trial.  
Normality was assessed with the Shapiro-Wilk test. Normally distributed 
data were compared in all studies by means of the Student’s t test or one-way 
analysis of variance. Mann−Whitney U or Kruskall−Wallis tests were used 
for data showing non-Gaussian distributions. Tukey HSD and Games-Howell 
post hoc comparisons were used for parametric and non-parametric data 
respectively. Wilcoxon’s signed rank test was used for within-groups 
comparisons and for within group comparisons of treatment effects (Studies 
IV and V) when appropriate.  
To explore the impact of hot flushes on the cardiovascular autonomic 
nervous testing variables during HT (Studies IV and V), a two-way between 
groups ANOVA with analysis of covariance was used. A univariable instead of 
multivariable approach was used due to the multicollinearity between the 
investigated variables. The effect of treatment (partial eta2, η2) was assessed 
as the absolute change after HT controlling for possible confounding factors 
(the baseline value of the variable in question, time since the last 
menstruation, the levels on E2) expressed as percentages from baseline. 
Pearson’s test was used for correlating normally distributed variables and 
Spearman’s rho for correlating non-normally distributed variables (Studies I 
and II). A Chi-square test for independence, multiple and logistic regression 
analyses were used to explore the predictive value of premenstrual symptoms 
and the relation of premenstrual and postmenopausal vasomotor symptoms 
(Study II).  
A p-value <0.05 was considered statistically significant.  Data are 
expressed as mean ± standard deviation (SD) (Study I, III) or mean ± 
standard error of mean (SEM) (Studies II, IV, and V), regardless of the 
variables’ distribution pattern. All analyses were performed by using SPSS 
16.0-20.0 software for Windows (SPSS Inc., Chicago, IL, USA). 
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RESULTS 
The main results are presented here, and more detailed results are found 
in the original publications attached.  
 
In women with and without hot flushes, the main baseline characteristics 
were similar, except that the time since last menstruation was shorter in 
women with hot flushes than in women without hot flushes (16.9±1.2 vs. 
21.9±1.1 months, p=0.001) (Table 11). 
 
Table 11. Baseline characteristics of the studied 150 women. Data are presented as mean ± SD. 
 
 
Hot flushes 
 
 Yes 
(n=72) 
No 
(n=78) 
p-value 
 
Age (years) 52.5±2.4 52.9±2.0 0.246 
Body mass index (kg/m2) 22.8±2.4 23.1±2.2 0.454 
Hot flush weekly weighted symptom score 161.2±65.5 7.0±8.4 <0.001 
Serum follicle stimulating hormone(IU/L) 67.9±22.9 78.1±29.3 0.052 
Serum estradiol (pmol/L) 80.8±86.5 58.7±60.2 0.142 
Age at menarche (years) 13.2±1.5 13.2±1.5 0.741 
Age at menopause (years) 50.5±3.3 50.9±2.6 0.600 
Time since last menstruation (months) 16.9±1.2 21.9±1.1 0.001 
Heart rate at rest (beats/min) 67.4±9.4 68.0±8.3 0.714 
Systolic blood pressure at rest (mmHg) 121.1±14.3 119.8±16.2 0.606 
Diastolic blood pressure at rest (mmHg) 83.2±8.9 80.6±9.0 0.166 
History of hormonal contraception (%) 71.8 66.7 0.496 
Deliveries 1.9±0.1 1.8±0.1 0.887 
Weekly use of alcohol (%) 60.0 60.3 0.975 
Employed (%) 94.4 96.2 0.496 
Absence from work (last 6 month) (%) 33.8 35.4 0.838 
In relationship (%) 68.6 74.4 0.436 
Sleep disturbances (%) 73.2 34.2 0.0001 
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Impact of hot flushes on health-related 
quality of life (Study I) 
Hot flushes impaired HRQL assessed by the WHQ. Poor sleep, impaired 
memory, concentration, and sexuality, somatic and depressive symptoms, 
and feeling less attractive, were more common in women with hot flushes. 
The severity of hot flushes, quantitated with HFWWS, correlated with poor 
sleep (correlation coefficient r=-0.525, p<0.0001), somatic symptoms       
(r=-0.348, p<0.0001), menstrual cycle-resembling complaints (r=-0.304, 
p<0.0001), anxiety and fears (r=-0.283, p< 0.0001), impaired memory and 
concentration (r=-0.279, p=0.001), and sexuality (r=-0.174, p=0.035). No 
association emerged between HFWWS and depression or feelings of 
attractiveness.  
 
The severity of hot flushes also correlated negatively with women’s 
subjective evaluation of their general health status with VAS (correlation 
coefficient r=-0.227, p=0.005). Thus, more troublesome hot flushes related 
to a worse perception of general health. 
 
Insomnia and sleep disturbances, irritability, exhaustion, depressive 
mood, joint pains, palpitation, nausea, and edema were significantly more 
common in women with than without hot flushes and also correlated to 
HFWWS. Women with severe hot flushes (HFWWS ≥100) had more sexual 
problems (pain during intercourse and insufficient lubrication) than 
asymptomatic women (HFWWS=0) (5.8±0.3 vs. 4.3±0.4, p=0.015). 
Otherwise, hot flushes were no determinants for sexual wellbeing measured 
with MFSQ. 
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Association between premenstrual 
symptoms and postmenopausal hot flushes 
(Study II) 
Of the 120 women responding to the PSST, 107 (89.2%) reported a history 
of premenstrual symptoms, and in 52 women (43.3%) these symptoms had 
been moderate or severe. Premenstrual symptoms interfered with work 
efficiency, relationships at work or at home, home responsibilities or social 
life activities in 64 women (53.3%). The mean PSST score among all women 
was 7.9±0.7, ranging from 0 to 38. The PSST score and the HFWWS score 
lacked significant correlation (r=0.087, p=0.346), indicating that women 
with a history of severe premenstrual symptoms were not more likely to 
experience severe hot flushes during their menopause. The PSST scores 
showed non-significant differences between women with none (7.8±1.4), 
mild (5.0±1.0), moderate (7.7±1.3), and severe (9.4±1.2) hot flushes (Figure 
8). 
 
 
Figure 8.  Scores of Premenstrual Symptoms Screening Tool (PSST) in women with and without 
postmenopausal hot flushes of different degrees of severity.  
Data are presented as mean ± SEM. 
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Although premenstrual symptoms and postmenopausal hot flushes lacked 
clear correlation, the severity of premenstrual symptoms in fertile age 
associated with a more problematic postmenopause in terms of increased 
mood symptoms and a decline in memory and concentration capacity, 
quality of sleep and personal feelings of attractiveness (Table 12). 
 
 
 
Table 12. Correlations between Women’s Health Questionnaire (WHQ) domains and 
Premenstrual Symptoms Screening Tool (PSST) score in recently postmenopausal women 
(n=120).  
Data are presented as mean ± SEM. 
 
WHQ domain value  
 
Correlation to PSST score 
(r) 
p-
value 
Depression 0.885±0.016 -0.263 0.023 
Sleep 0.719±0.032 -0.282 0.011 
Attractiveness 0.755±0.037 -0.260 0.022 
Memory and 
concentration 
0.726±0.031 -0.448 <0.001 
Anxiety 0.904±0.018 -0.214 0.056 
Vasomotor 0.480±0.047 -0.062 0.587 
Somatic  0.750±0.022 -0.167 0.139 
Menstrual  0.832±0.023 0.047 0.679 
Sexual 0.709±0.037 -0.089 0.493 
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Impact of hot flushes on cardiovascular 
autonomic responsiveness (Study III) 
Blood pressure 
Resting blood pressures were comparable between women with no, mild, 
moderate, and severe hot flushes (Figure 9). In response to active posture 
change from supine to upright, the diastolic blood pressure increased 
(p<0.0001) compared with supine levels (Figure 9, panel a). During the 
handgrip test, both systolic and diastolic blood pressures increased 
significantly (Figure 9, panel b). The observed blood pressure responses to 
active orthostatic and handgrip tests were normal, and no significant 
differences between the study groups emerged. Women with hot flushes 
(mild, moderate, and severe groups combined) had slightly lower maximal 
systolic (140±2 vs. 145±3 mmHg, p=0.123) and diastolic (92±1 vs. 95±2 
mmHg, p=0.081) blood pressures during the handgrip test than 
asymptomatic women. 
 
 
Figure 9. Responses of systolic and diastolic blood pressure to a) active orthostatic and b) 
handgrip tests in women with and without hot flushes. 
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Heart rate 
Resting HRs (no hot flushes 69±10 beats/min, mild 66±7 beats/min, 
moderate 69±9 beats/min, and severe 67±9 beats/min, p=ns between 
groups) and maximal HRs during active orthostatic, handgrip, or Valsalva 
tests were equivalent between the study groups. During the Valsalva 
manoeuvre, the HR increased, and the release of strain was followed by 
reflex bradycardia. The Tachycardia ratio was lower in women with hot 
flushes compared with women without hot flushes, reflecting a stronger HR 
acceleration during Valsalva relative to the resting HR (Figure 10, panel a). 
This difference became evident when all women with hot flushes of different 
severities were combined into a single group and compared with 
asymptomatic women. The Valsalva ratio was slightly higher in women with 
hot flushes compared with women without hot flushes (Figure 10, panel b). 
Furthermore, results from the deep breathing and active orthostatic tests 
support these findings showing a tendency towards a more pronounced HR 
elevation in women with hot flushes (Figure 10, panels c and d).   
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Figure 10. Responses of heart rate to cardiovascular autonomic tests in women with and without 
hot flushes.  Median/mean values of each group are indicated in numeric form above the x-axis. 
Line at mean (panels a, b) or median (panels c, d). 
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Heart rate variability 
The HRV in time (Table 13) or frequency domain measured at rest and 
during controlled and deep breathing lacked association with the hot flush 
status. A change of position from supine to standing caused expected 
increases in LF power and decreases in HF power equally in all study groups 
(p<0.01 for all), but HRV variables showed no relation to hot flush severity, 
neither in time (Table 13) nor frequency domain. 
 
Table 13. Heart rate variability in time domain during controlled and deep breathing and active 
orthostatic test in 148 women with different hot flush severities. 
 
 Hot Flushes 
 
 None 
(n=23)  
Mild  
(n=33) 
Moderate  
(n=29) 
Severe  
(n=63) 
Controlled breathing     
              RMSSD (ms) 26 (11-77) 23 (12-83) 23 (8-76) 26 (9-196) 
              CoV (%)                     2.4 (1.6-7.2) 2.6 (1.5-7.4) 2.4 (1.1-9.2) 2.7 (1.1-21.3) 
Deep breathing     
             RMSSD (ms) 43 (12-130) 40 (15-89) 46 (8-125) 41 (11-172) 
             CoV (%) 5.1 (2.4-16.0) 4.5 (2.2-9.1) 5 (1.3-14.3) 4.5 (2.0-18.1) 
Active orthostatic (standing)      
              RMSSD (ms) 16 (6-72) 18 (8-46) 18 (7-95) 17 (10-94) 
              CoV (%)                     2 (0.9-6.9) 2.2 (1.1-5.3) 2.1 (0.9-7.8) 2.1 (1.1-11.6) 
Active orthostatic (Δ)       
              RMSSD (ms) -13 (-53-9) -11 (-55-12) -4 (-39-32) -10 (-154-33) 
              CoV (%)                     -0.8 (-4.3 -1.0) -0.8 (-4.0-1.6) -0.1 (-3.7-3.9) -0.7 (-15.3-2.7) 
     
Data are presented as median (range), p=ns between all study groups 
Δ Change from supine to standing position 
RMSSD = the square root of the mean of the sum of squares of adjacent 
normal-to-normal R-R intervals 
CoV = Coefficient of variation = HRV in proportion to mean R-R interval 
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Associations between cardiovascular 
autonomic function and a history of 
premenstrual symptoms  
(unpublished data) 
 
 
To evaluate if a history of severe premenstrual symptoms would be an 
independent factor in the autonomic regulation in menopausal women, we 
compared women having severe premenstrual and severe vasomotor 
symptoms (PSST score ≥15, HFWWS ≥100) and women with mild or no such 
symptoms at all (PSST score ≤3, HFWWS ≤9.5). Women with severe 
symptoms had a higher Valsalva ratio (1.951±0.056 vs. 1.639±0.057, 
p=0.005) and a more pronounced elevation of HR during strain (37.3±1.1 vs. 
30.6±2.6 beats/min) than women with mild symptoms. Furthermore, when 
comparing women having both severe premenstrual and vasomotor 
symptoms (PSST score ≥15, HFWWS ≥100) with women having severe 
vasomotor symptoms but only mild premenstrual symptoms (PSST score ≤3, 
HFWWS ≥100), the above-mentioned differences persisted (Figure 11). In 
addition, women with both severe premenstrual and vasomotor symptoms 
had a lower Tachycardia ratio compared with women with mild premenstrual 
symptoms (Figure 11, panel b). 
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Figure 11. Heart rate responses during Valsalva manoeuvre in women with severe 
postmenopausal hot flushes but a history of either mild/none or severe premenstrual symptoms;  
a) Valsalva ratio, b) Tachycardia ratio, and c) heart rate change during strain. (Lines at mean). 
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Effects of hormone therapy on 
Hormone levels 
All oral and transdermal ET, and ET+ MPA  treatments  led to significant 
elevations in serum E2 levels  compared with placebo treatments (p<0.01). 
All active treatments also reduced hot flushes effectively (p<0.01 for all 
compared with placebo, p<0.0001 compared with baseline level), but also 
placebos caused a modest 23% reduction in HFWWS from baseline. (Table 
14) 
 
 
Table 14. Levels and changes in estradiol (E2) and hot flush weekly weighted symptom score 
(HFWWS) after six months of hormone therapy.  
Data are presented as mean ± SEM.  
MPA=medroxyprogesterone acetate 
 
 
 Oral E2 Transdermal E2 Oral E2  
and MPA 
Placebo 
  
E2 (pmol/L) 
 
218±18* 204±29* 174±15* 69±17 
Change of E2 (pmol/L) +157±22* +125±33* +106±19* -3±20 
In women with pre-
treatment hot flushes: 
 
    
HFWWS  6±3* 35±15* 4±2* 113±19 
Change of HFWWS  
(% from baseline) 
-96±1* -80±7* -97±1* -23±16 
*p <0.0001 compared with placebo 
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Health-related quality of life (Study I) 
 
In women with pre-treatment hot flushes, HT significantly improved 
scores of the WHQ domains regarding vasomotor symptoms (0.741±0.410 
vs. 0.042±0.129, p<0.0001), sleep (0.787±0.268 vs. 0.556±0.249, p=0.001), 
anxiety and fears (0.942±0.133 vs. 0.826±0.193, p=0.005), and memory and 
concentration (0.849±0.228 vs. 0.454±0.301, p<0.0001) compared with 
placebo treatment. At three months, placebo treatment also improved some 
of the WHQ scores compared with baseline levels (vasomotor symptoms 
+0.208, p=0.044, sleep +0.139, p=0.022, anxiety and fears +0.125, 
p=0.028), but these positive effects were no longer evident after the six 
month treatment. In women without hot flushes, HT slightly improved 
memory and concentration from the baseline level (0.803±0.273 to 
0.917±0.178, p=0.026) and reduced insomnia (1.635±0.864 to 1.386±0.618, 
p=0.012). 
Hormone therapy significantly relieved exhaustion (1.9±0.8 vs. 2.5±0.8, 
p=0.006), irritability (1.9±0.7 vs. 2.3±0.8, p=0.011), edema (1.5±0.8 vs. 
1.7±0.5, p=0.041), joint or muscle pains (1.8±1.0 vs. 2.2±0.8, p=0.013), and 
vaginal dryness (1.3±0.6 vs. 2.1±1.0, p=0.002), compared with placebo 
recipients in women with pre-treatment hot flushes, whereas HT did not 
relieve depressive mood (1.3±0.5 vs. 1.4±0.6, p=0.341) or insomnia (2.0±1.0 
vs. 2.4±1.0, p=0.051). Irritability was more common among non-flushing 
women receiving HT compared with placebo users (1.7±0.7 vs. 1.4±0.8, 
p=0.024). Otherwise, HT effects on menopausal symptoms were neutral in 
women without hot flushes.  
 In women with (but not without) pre-treatment hot flushes, HT improved 
the general health (2.0±0.3 vs. 1.8±0.5, p=0.040) compared with placebo 
treatment. However, HT did not affect sexual wellbeing (sexual satisfaction, 
sexual problems, or satisfaction with the partner) in women with or without 
flushes. 
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Blood pressure (Study IV) 
In women with pre-treatment hot flushes, HT lowered the systolic and 
diastolic resting blood pressure (Figure 12, panel a). Estradiol therapy 
decreased flushing women’s diastolic blood pressure compared with a slight 
elevation in non-flushing women (−4.0±1.2 mmHg in women with hot 
flushes vs. 0.9±1.5 mmHg in women without hot flushes, p=0.045). Placebos 
also reduced the resting blood pressure in women with hot flushes.  
After HT, the systolic and diastolic blood pressure increases in response 
to the handgrip test were more pronounced in women with pre-treatment hot 
flushes than in asymptomatic women, particularly with ET (Figure 12, panel 
b). In contrast, in women without hot flushes, the diastolic blood pressure 
increased less after ET compared with flushing women (−2.3±1.4 vs. 5.1±1.5 
mmHg, p=0.003). However, blood pressure responses to the handgrip test 
between the different treatment groups were comparable (Figure 12, panel 
b).  
Active standing caused similar responses in blood pressure in all study 
groups, and the responses related neither to hot flush status nor HT 
regimens.
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Figure 12. Change in a) resting blood pressure and b) blood pressure response to handgrip 
strain in women with and without pre-treatment hot flushes after 6 months hormone therapy. Data 
are expressed as mean ± SEM. # compared with the level before treatment ET = estradiol 
therapy, MPA = medroxyprogesterone acetate, BP = blood pressure   
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Heart rate (Study IV) 
In women with pre-treatment hot flushes, ET reduced the resting HR 
compared with placebo treatment (-2.2±0.7 vs. 1.3±1.1 beats/min, p=0.03). 
Estradiol + MPA, however, slightly increased the resting HR (+0.7±1.2 
beats/min) in women with hot flushes. Women with hot flushes also showed 
attenuated HR responses during the handgrip test after ET compared with 
placebo users (-2.2±1.3 vs. 2.8±1.5 beats/min, p=0.038), whereas ET + MPA 
increased the maximal HR during the handgrip compared with ET (3.1±1.4 
vs. -2.2±1.3 beats/min, p=0.02).  Similar, although non-significant, effects of 
HT on maximal HRs were seen during active orthostatic and Valsalva tests in 
women with pre-treatment hot flushes. Neither hot flushes nor HT 
influenced the deep breathing-induced oscillations of the HR, the Valsalva or 
Tachycardia ratios during Valsalva strain, or the 30/15 -ratio during 
standing. 
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Heart rate variability (Study V) 
 
Hormone therapy did not affect HRV in time domain or in frequency 
domain measurements (HF, LF or LF/HF ratio) in women with or without 
pre-treatment hot flushes. However, during controlled quiet breathing, HT 
reduced VLF power in women with hot flushes compared with baseline level 
(p=0.018, Figure 13) and with non-flushing women (258±28 vs. 441±70 ms2, 
p=0.025). Women without hot flushes receiving a placebo showed smaller 
changes of normalised HF and LF after standing up than women in other 
groups (nHF -0.016±0.050 vs. -0.166±0.026, nLF 0.002±0.069 vs. 
0.173±0.029, p≤0.015 between women without hot flushes after placebo and 
women with hot flushes after HT). 
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Figure 13. Very low frequency power (VLF) at baseline and after treatment in women with pre-
treatment hot flushes during controlled quiet breathing.   
Data are presented as mean ± SEM. 
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Table 15. Subjects, methods and main results of the original studies. 
 
Study 
 
Study 
population 
Treatment Outcome 
measures 
Results 
I 
HRQL and sexual 
function in women 
with and without 
hot flushes 
n=132 
 
6 months 
-Oral E2 2mg 
-Oral E2 2mg+   
MPA 5mg 
-Transdermal 
E2 1mg 
-Placebo 
WHQ  
MFSQ 
VAS 
Kupperman 
index 
-Women with hot flushes had generally 
worse HRQL than women without hot 
flushes  
-HT improved vasomotor and other 
menopausal symptoms and scores of 
general health, memory and 
concentration, anxiety, and sleep 
II 
Association 
between 
premenstrual and 
menopausal 
symptoms 
n=120 
 
 
- History of 
premenstrual 
symptoms, 
menopausal 
HRQL 
PSST, WHQ 
-Severity of premenstrual symptoms 
lacked correlation with hot flushes but 
associated with deteriorated 
menopausal HRQL 
III 
Cardiovascular 
autonomic function 
in women with hot 
flushes of different 
severities 
n=150 
 
- Responses of 
blood pressure, 
HR and HRV to 
autonomic 
testing 
-Hot flushes associated with  
tachycardic HR responses 
-Comparable HRV 
-Comparable blood pressure 
 
IV 
Impact of HT on 
cardiovascular 
autonomic function 
in women with and 
without hot flushes 
n=138 
 
6 months 
-Oral E2 2mg 
-Oral E2 2mg+ 
MPA 5mg 
-Transdermal 
E2 1mg 
-Placebo 
Responses of 
blood pressure 
and HR to 
autonomic 
testing 
-HT lowered resting blood pressure and 
augmented blood pressure response to 
strain in women with hot flushes 
-E2 lowered resting HR and HR 
responses to strain in women with hot 
flushes, whereas E2+MPA acted 
reciprocally 
V 
Impact of HT on 
HRV in women 
with and without 
hot flushes 
n=138 
 
6 months 
-Oral E2 2mg 
-Oral E2 2mg+ 
MPA 5mg 
-Transdermal 
E2 1mg 
-Placebo 
HRV during 
autonomic 
testing 
-HT did not affect HRV in women with 
or without hot flushes 
 
HRQL = Health-related quality of life, E2 = estradiol, MPA = Medroxyprogesterone acetate, 
HT = hormone therapy, WHQ = Women’s health questionnaire, MFSQ = McCoy female 
sexual questionnaire, VAS = Visual analogue scale, PSST = Premenstrual symptoms 
screening tool, HR = heart rate, HRV = heart rate variability 
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DISCUSSION 
Quality of life is of vital importance in women’s general wellbeing 
throughout their different life stages. Research on women’s HRQL is gaining 
much interest along with longer life expectancy, and since a worsened quality 
of life can impair a woman’s working capacity, it can even result in absence 
from work. In particular, hot flushes, mood swings, poor sleep, physical 
complaints, and disturbances of memory and concentration are generally 
thought to deteriorate menopausal women’s HRQL (Hess et al. 2012, Ayers & 
Hunter 2013). However, it has not been concluded whether hot flushes are the 
major determinant for a worsened HRQL. According to some theories non-
flush symptoms could be only secondary phenomena to hot flushes. Hot 
flushes show great day-to-day variation, and women’s capacity to tolerate hot 
flushes varies considerably (Freeman et al. 2005). Therefore, the use of 
multiple menopause-specific HRQL instruments, careful and prospective 
assessment of hot flushes and other menopausal symptoms are essential, as 
done in the present study.  
The background mechanisms of hot flushes have remained unclear, 
although increasing evidence of the cardiovascular autonomic function’s 
involvement has been gained during the course of our study (Thurston et al. 
2010, Freedman et al. 2011, Thurston et al. 2012). Interestingly, as menopausal 
and premenstrual symptoms share many similarities, changes in 
cardiovascular autonomic function are also seen in women with severe 
premenstrual symptoms. 
Hot flushes and postmenopausal health-related quality of 
life 
The current study shows that hot flushes are major determinants in 
decrease of HRQL, as they associated with worsened general health 
perception and with all domains of the WHQ. Previous studies have yielded 
inconclusive results on the relationship of hot flushes and memory 
deterioration (LeBlanc et al. 2007, Maki et al. 2008, Greendale et al. 2010, 
Schaafsma et al. 2010, Mitchell & Woods 2011), possibly due to many different 
methods. In our study, women with hot flushes experinced more subjective 
difficulties with memory and concentration than women without hot flushes, 
and the difficulties correlated with the severity of hot flushes. Although 
women with hot flushes reported more depressive symptoms than their 
asymptomatic counterparts, depressive scores lacked correlation with the 
severity of hot flushes (HFWWS). This likely implies that depressive mood is 
an independent symptom apart from hot flushes. Depressive symptoms have 
preceded the occurrence hot flushes around menopause (Freeman et al. 2009), 
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supporting our results, although women with depressive symptoms in 
menopause are more likely to report hot flushes (Freeman 2010). 
 
Hot flushes were effectively reduced with all HT regimens. Hormone 
therapy alleviated poor sleep and anxiety, and it enhanced memory and 
concentration capacity in women with pre-treatment hot flushes. Previous 
trials, such as WHI and HERS, included mainly asymptomatic women well 
past the menopause and are therefore likely to underestimate the positive 
effects of HT on HRQL for women with hot flushes.  
 
The present study shows that in women without pre-treatment hot 
flushes, HT improved memory and concentration capacity compared with 
the baseline, although such improvements were not detected in other HRQL 
areas. These findings may also support the “timing hypothesis” of HT also on 
memory; HT started in early postmenopause could have protective effects on 
memory (Henderson 2014, Rocca et al. 2014), both in women with and without 
hot flushes. Evidence of estrogen’s neuroprotective effect is convincing 
(Barrett-Connor & Laughlin 2009, Fischer et al. 2014), whereas an increasing 
amount of evidence suggests that MPA could be detrimental to cognitive 
function (Nilsen & Brinton 2002, Resnick et al. 2006, Liu et al. 2010, Irwin et al. 
2011). In our study, MPA did not counteract the positive effects of E2 on 
HRQL parameters during the six months treatment period. It is possible that 
MPA effects are different in recently postmenopausal women compared to 
older women assessed in the previous studies (Resnick et al. 2006, Veerus et al. 
2012).  
 
Hormone therapy did not improve depressive mood significantly in the 
present study. A recent Finnish registry finding revealed that HT-use is 
associated with depression (Toffol et al. 2012), which could imply that women 
with depressive symptoms are more likely to use HT. Some other (Soares et 
al. 2001, Hlatky et al. 2002), but not all randomised controlled trials  (Morrison 
et al. 2004, Hays et al. 2003, Welton et al. 2008) have found positive effects of 
HT on depressive symptoms in older women. Interestingly, in most HRQL 
variables, a placebo effect was detected at three months but not anymore 
after six months treatment. This emphasises the importance of the placebo 
arm also in HRQL studies, particularly in a short-term assessment. 
 
Evaluation of sexual function in a setting specifically comparing women 
with or without hot flushes after natural menopause, has not been previously 
reported. It has been shown that after surgical menopause, women tend to 
experience more menopausal symptoms, which associate with sexual 
dysfunction, than after natural menopause (Topatan et al.2012). In the present 
study, severe hot flushes associated with sexual problems, but not with 
generally poorer sexual function measured with the specific menopausal 
MFSQ. Neither did the hot flush status influence HT’s effect on sexual 
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function.  Some (Welton et al. 2008, Gast et al. 2009), but not all (Hays et al. 
2003, Wierman et al. 2010) studies have shown beneficial effects of HT on 
sexual function. Local and systemic HT indisputably alleviates vaginal 
dryness and concomitant dyspareunia. Since the women in the present study 
were recently menopausal, vaginal epithelial atrophy might not yet have 
developed. This could at least in part explain the differing results compared 
to the previous studies with elderly women (Welton et al. 2008, Gast et al. 
2009). 
 
Premenstrual and postmenopausal symptoms 
In the present study, the severity of premenstrual symptoms during fertile 
years lacked association with hot flushes. Thus, my data indicate that women 
with premenstrual symptoms are not at increased risk to develop vasomotor 
symptoms when they reach menopause. Instead, premenstrual symptoms 
correlated with poor sleep, depressive symptoms, impaired memory and 
concentration capacity and feelings of less attractiveness recently after 
menopause. It is possible that the retrospective assessment of premenstrual 
symptoms could affect the reliability in recalling the symptom severity. In 
previous studies, premenstrual symptoms and hot flushes had associated in 
two studies (Collins & Landgren 1994, Freeman et al. 2004) but lacked 
association in two other studies (Guthrie et al. 1996, Morse et al. 1998). Varying 
methods explain, at least in part, the differing findings of the previous 
studies and also compared with this study. For example, in the previous 
follow-up studies, evaluation of hot flushes was retrospective and lacked a 
severity rating, or the assessment of premenstrual symptoms was limited.   
Premenstrual symptoms are characterised by mood swings and 
depressive feelings. Women with PMS have more diagnosed depression than 
the general population (Halbreich 2003), and a recent review outlined that 
menopausal women also have an elevated risk for depression (Llaneza et al. 
2012). These results support our findings, showing that premenstrual 
symptoms correlate with depressive mood at menopause. It is possible that 
women with premenstrual symptoms are vulnerable for mood symptoms 
throughout the different stages of their reproductive life, including the 
menopause. The finding that the history of premenstrual symptoms 
associated with depressive mood, poor sleep and memory but not with hot 
flushes might indicate that these menopausal complaints affect women’s 
HRQL independently, and are not just secondary to hot flushes. 
 
Although the underlying mechanisms of both premenstrual and 
menopausal symptoms remain unclear, alterations involving the 
cardiovascular autonomic nervous system have been related to both 
premenstrual symptoms (Girdler et al. 1998, Matsumoto et al. 2006, 
Matsumoto et al. 2007) and menopausal transition (Brockbank et al. 2000). 
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Previous data indicates possibly reduced HRV during the luteal phase in PMS 
patients (Matsumoto et al. 2006, Matsumoto et al. 2007, Baker et al. 2008) 
and generally reduced HRV in PMDD patients (Landen et al. 2004, 
Matsumoto et al. 2007).  
To shed light on the suggested role of cardiovascular autonomic function 
in premenstrual and postmenopausal symptoms, we compared the 
cardiovascular autonomic responses of women with both severe 
premenstrual and vasomotor symptoms to those having only mild 
premenstrual and vasomotor symptoms. Women with the most severe 
premenstrual symptoms and hot flushes reacted with a more pronounced HR 
increase during the Valsalva manoeuvre than women with mild premenstrual 
and vasomotor symptoms. The HR increase during the Valsalva manoeuvre 
is mediated both by a surge in sympathetic activity and a rapid withdrawal of 
parasympathetic tone. To further investigate the role of previous 
premenstrual symptoms possibly affecting cardiovascular autonomic 
responses in menopause, we compared women with severe premenstrual 
symptoms and hot flushes to those who had severe hot flushes but only mild 
or absent premenstrual symptoms. The differences in HR responses to 
Valsalva were similar to the former comparison groups. This implies that 
women with previous severe premenstrual symptoms could possess more 
sympathetic drive, irrespective of hot flushes. This finding suggests that 
qualities involving the cardiovascular autonomic nervous system could act as 
background mechanisms of premenstrual symptoms. 
Hot flushes and cardiovascular autonomic function 
 
Exploring the impact of hot flushes on cardiovascular autonomic 
regulation before and during HT was one of the primary goals of this 
research. We hypothesised that cardiovascular function in women with hot 
flushes might differ from that of asymptomatic women.  
Hot flushes have been linked to various cardiovascular risk factors, such 
as endothelial dysfunction (Thurston et al. 2008, Bechlioulis et al. 2009), 
increased calcification of the aorta (Thurston et al. 2008), higher carotid intima 
media thickness (Thurston et al. 2011b), and unfavorable lipid profile (Gast et 
al. 2008). On the contrary, the recent findings of the Kronos Early Estrogen 
Prevention Study show that vasomotor symptoms do not associate with 
subclinical atherosclerosis evaluated with coronary artery calcium and 
carotid intima-media thickness (Wolff et al. 2013). Previous studies on the 
association between hot flushes and elevated blood pressure have also 
resulted in inconsistent findings (Nelesen et al. 2004, Gast et al. 2008, Gallicchio 
et al. 2010, Gast et al. 2010). The autonomic nervous system is the main short-
term regulator of blood pressure and is also involved in the long-term control 
(Joyner et al. 2008). After menopause and along with aging the increased 
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sympathetic activity leading to vasoconstriction could promote the 
development of hypertension (Barton & Meyer 2009, Barnes et al. 2014, Hart & 
Charkoudian 2014). On the other hand, calcification and atherosclerosis of 
blood vessels diminishes the vascular reactivity and could thereby deteriorate 
cardiovascular autonomic regulation. Altogether, endogenous and exogenous 
estrogens appear to have an inhibitory role on the sympathetic activity 
(Mercuro et al. 2000), and the reduced parasympathetic input in 
postmenopausal women, possibly due to hypoestrogenism, leaves the 
cardiovascular system exposed to unopposed sympathetic stimulation.  
 
In this study, women with hot flushes compared to non-flushing women 
show slightly smaller rises in systolic and diastolic blood pressures during 
isometric muscle contraction, provoking sympathetic activation. This novel 
finding could be explained at least in part by functional differences at the 
vascular level (Tuomikoski et al. 2009a). The flushing women might have a 
smaller vasoconstriction reserve due to the higher underlying sympathetic 
tone in the vasculature. This could diminish the additional sympathetic 
response provoked by a handgrip test leading to smaller blood pressure 
elevations than in asymptomatic women. 
After menopause women are thought to have more sympathetic drive and 
attenuated parasympathetic activity than younger women (Lavi et al. 2007, 
Yang et al. 2013). Whether this shift is due to just advancing age or truly to 
menopause related changes in estrogen metabolism is unclear. Our data 
showed increased sympathetic activity and slightly blunted parasympathetic 
HR responses in these recently postmenopausal women, suggesting that the 
previously seen menopausal change in autonomic activity would result from 
menopause per se, not just aging. Moreover, as this phenomenon related to 
hot flushes, the hot flush status could be an important determinant.  
 
Hot flushes lacked association with HRV in this controlled short-term 
setting. This is in line with our earlier findings seen in ambulatory HRV 
measurements in recently postmenopausal women (Hoikkala et al. 2010). One 
rather small study, using a short-term HRV measurement, associated 
menopausal symptoms and hot flushes with higher LF/HF-ratio indicating 
increased sympathetic activity (Lee et al. 2011). Heart rate variability is a 
sensitive attribute of autonomic regulation and has been reduced after 
menopause (Brockbank et al. 2000). Attenuated HRV is seen also in CVDs 
(Buccelletti et al. 2009). In terms of HRV, our results indicate that hot flushes 
do not associate with impaired autonomic regulation of the HR. During hot 
flushes, parasympathetic withdrawal has been detected in short-term 
measurements (Thurston et al. 2010b) and in an ambulatory setting during 
daytime and sleep (Thurston et al. 2012). Increases in LF power indicating 
rises in sympathetic activity (Freedman et al. 2011) and decreases in HF power 
as a sign of vagal withdrawal (de Zambotti et al. 2013) were detected during 
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nighttime ambulatory measurements. These data suggest a significant 
contribution of autonomic regulation in hot flushes.  
 
In addition to studying the impact of hot flushes on cardiovascular 
autonomic function in a cross-sectional setting, the present study assessed 
the impact of hot flushes on outcomes of HT in a prospective, randomised 
trial. Previous data on the effects of HT on cardiovascular autonomic 
function are inconclusive, probably due to the diversity in methodologies and 
HT components. Only one study has compared flushing and non-flushing 
women, but without any placebo-control (Beljic et al. 1999). In our study, hot 
flushes were accompanied with reductions in resting blood pressures and 
HRs and in responses of HR to cardiovascular autonomic function tests after 
ET. Lowered resting blood pressure after ET is in line with our previous 
results in ambulatory measurements, as E2 decreased 24-hour and daytime 
blood pressures in women with hot flushes (Tuomikoski et al. 2010). In the 
present study however, blood pressures elevated more during the handgrip 
test in women with pre-treatment hot flushes than in women without hot 
flushes. This might suggest that E2 restores the vascular reactivity, which is 
reduced due to the sympathetic overdrive associated with menopause and 
hot flushes, and further improves the vasculature’s reactivity to physical 
strain. These results indicate that the potentially beneficial effect of estrogen 
on autonomic nervous function is seen particularly in women with hot 
flushes. It is not possible to deduce whether these effects are secondary 
consequences of vanished hot flushes or a direct effect of E2 on the 
autonomic regulation of blood pressure and HR.  
 
The present results show neutral effects of HT on HRV in controlled 
short-term measurements, regardless of the route of HT administration. 
These results were not affected by the hot flush status. Our study group has 
earlier observed potentially unfavorable effects of HT on nighttime HRV in 
ambulatory measurements (Lantto et al. 2012). These were seen regardless of 
the pre-treatment hot flush status. The HT effects seen in the nighttime 
ambulatory assessment could be explained by indirect autonomic influences 
of sleep and HRV in its different stages (Ako et al. 2003, Versace et al. 2003). 
Previously in the same ambulatory setting, VLF power during nighttime hot 
flushes was increased (Hoikkala et al. 2010). In the present study, HT 
attenuated VLF in women with pre-treatment hot flushes. The physiological 
source of VLF has remained unclear, but it has been associated with 
peripheral vasomotor regulation (Perini & Veicsteinas 2003), 
thermoregulation, and the renin-angiotensin system (Taylor et al. 1998). This 
could relate to alleviation of hot flushes and further to HT’s effects on 
thermoregulation or the vasculature.   
 
The hot flush has emerged as one possible determinant for the conflicting 
estrogen mediated vascular effects (van der Schouw & Grobbee 2005, Mikkola 
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2011, Tuomikoski et al. 2011). Some studies have associated hot flushes with an 
adverse cardiovascular risk profile (Gast et al. 2008, Gast et al. 2010, Huang et 
al. 2009), but our study group has shown that in recently menopausal women, 
hot flushes were accompanied by vasodilatory effects (Tuomikoski et al. 2009a) 
and furthermore, the effect of E2 on vascular function depends on the pre-
treatment hot flush status (Tuomikoski et al. 2009b). In our studies, the 
responses to E2 with or without concomitant MPA were neutral in terms of 
vasoconstriction or vasodilatation in women with hot flushes, whereas in 
women without hot flushes E2 induced a vasoconstrictive response. These 
findings also gain support from the re-analysis of the WHI study results 
showing that vasomotor hot flushes at the onset of menopause, but not later 
after menopause, were associated with reduced cardiovascular events 
(Szmuilowicz et al. 2011). The mechanisms behind these findings might relate 
to differences in cardiovascular autonomic regulation. 
 
The progestogen component, particularly MPA, may modify the effects of 
HT (Kuhl & Stevenson 2006, Sitruk-Ware 2007, Scarabin et al. 2011, Yang et al. 
2013). In our study, MPA attenuated the potentially beneficial effects of ET 
on resting HR and on HR response to the handgrip test in women with pre-
treatment hot flushes.  The large placebo controlled studies (WHI-EPT, 
HERS) have associated MPA-containing HT with adverse cardiovascular 
events (Grodstein et al. 2003). Medroxyprogesterone acetate has been also 
suggested to predispose to arrhythmias (Gökce et al. 2005, Lantto et al. 2012). 
This progestin has androgenic, antiestrogenic, and glucocorticoid features 
(Kuhl 2005), which may counteract the effects of estrogen. 
Strengths and limitations 
 
The study population was carefully selected to represent healthy, recently 
postmenopausal women without cardiovascular risk factors in order to 
investigate the impact of hot flushes on HRQL and cardiovascular autonomic 
function. Other strengths of our study are the prospective and validated 
assessment of hot flushes and application of multiple instruments in 
evaluating HRQL and other menopausal complaints. Cardiovascular 
autonomic function was assessed with a standardised laboratory test series in 
carefully controlled laboratory settings, expected to detect even slight 
differences in cardiovascular function and facilitating assessment of the 
relative contributions of the sympathetic and parasympathetic branches.  
For the HT part of our study, 150 participants were randomised to 
transdermal and oral E2 or the latter combined with MPA. This enabled 
comparison of the administration routes, which were suspected to vary 
knowing the differing estrogenic milieus they create. However, transdermal 
and oral estrogen affected HRQL and cardiovascular autonomic function 
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similarly in this study. The MPA was chosen as a progestin because it had 
been used in most of the previous large HT trials (Hulley et al. 1998, Rossouw 
et al. 2002).  
 
As limitations of the study, it should be noted that the participants were 
lean, healthy, and white, and thus, the results may not apply to obese women 
or those with diseases and medications or of other ethnic populations. 
Recruitment by a newspaper advertisement could affect the selection process 
toward healthier women. We studied recently postmenopausal women, and 
therefore this data may not hold for older women. It can be also speculated 
that a longer treatment period might have yielded additional differences. 
Finally, the number of women in our study was limited, and it is therefore 
possible that some differences remained undetected due to small sample 
sizes. 
 
Future directions 
 
In the future, research should assess effects of different progestins on 
cardiovascular autonomic function and memory. Lower doses of oral 
estrogen and the transdermal route are under active research (Harman et al. 
2005, ELITE). A novel treatment for menopausal symptoms, tissue-selective 
estrogen complex “TSEC” containing both estrogen and a selective estrogen 
receptor modulator, is being developed (Kagan 2012). Ideally, a TSEC would 
effectively alleviate hot flushes and prevent bone loss, lacking effects on the 
cardiovascular system, breast tissue, and endometrium. Larger, prospective 
studies are needed to confirm the impact of hot flushes on the outcomes of 
HT and to outweigh the quite large variation of individual autonomic 
responses.  Future trials should always consider the hot flush status as a 
possible determinant for HT effects.  
 
In conclusion, ET and EPT both alleviated hot flushes and improved 
HRQL equally well. A history of premenstrual symptoms appears to 
predispose women to worsened HRQL in menopause, but they are not at an 
increased risk of developing hot flushes, which is comforting for women 
having troublesome premenstrual symptoms. Hot flushes associate with 
increased sympathetic activity in regulation of the HR, which could be seen 
as an unfavorable factor for cardiovascular health. However, this can be 
reduced with ET, especially in women with pre-treatment hot flushes. Adding 
MPA to E2 seems to blunt some positive effects of ET. Oral and transdermal 
administration routes of E2 resulted in similar responses. Thus, the hot flush 
status contributes clearly to the quality of life and cardiovascular autonomic 
function before and during HT. Particularly women with hot flushes appear 
to benefit most from HT’s positive effects on the HRQL and cardiovascular 
regulation. 
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CONCLUSIONS 
The present studies on healthy, recently postmenopausal women allow 
the following conclusions: 
 
? Hot flushes are major determinants of menopausal decrease in health-
related quality of life, but not of sexual function. 
 
? Estrogen therapy and estrogen-progestogen therapy equally effectively 
improved health-related quality of life. Different administration 
routes of estrogen showed similar effects. 
 
? Premenstrual symptoms do not predict hot flushes, but they are in 
association with worsened health-related quality of life in menopause. 
 
? Hot flushes contribute to cardiovascular autonomic responsiveness. 
 
? Hot flushes were accompanied with beneficial effects of estrogen 
therapy on cardiovascular autonomic responsiveness, whereas 
combining medroxyprogesterone acetate with hormone therapy 
attenuated the potentially beneficial effects of estrogen. 
 
? Hot flushes lacked association with heart rate variability and hormone 
therapy’s effect on heart rate variability. 
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APPENDICES 
Appendix A. Questions of the Women’s Health Questionnaire answered on a 
four-point scale. (Yes definitely, Yes sometimes, No not much, No not at all). 
 
Vasomotor 
I have hot flushes 
I suffer from night sweats 
Somatic 
I have headaches 
I feel more tired than usual 
I have dizzy spells 
I suffer from backache or pain in my limbs 
I feel sick or nauseous 
I often notice ‘pins and needles’ in my hands and feet 
I need to pass urine/water more frequently than usual 
Anxiety and fears 
I get very frightened or panic feelings for apparently no reason at all 
I feel anxious when I go out of the house on my own 
I feel tense or ‘wound up’ 
I get palpitations or a sensation of ‘butterflies’ in my stomach or chest 
Depression 
I feel miserable and sad 
I have lost interest in things 
I feel life is not worth living 
I am more irritable than usual 
I still enjoy the things I used to 
I have a good appetite 
I have feelings of well-being 
Sleep 
I am restless and can’t keep still 
I have difficulty in getting off to sleep 
I wake early and then sleep badly for the rest of the night 
Sexual 
I have lost interest in sexual activity 
I am satisfied with my current sexual relationship (please omit if not sexually active) 
As a result of vaginal dryness sexual intercourse has become uncomfortable 
Memory and concentration 
I am more clumsy than usual 
I have difficulty in concentrating 
My memory is poor 
Menstrual 
My stomach feels bloated 
I have abdominal cramps or discomfort 
I have heavy periods (please omit if no periods at all) 
My breasts feel tender or uncomfortable 
Attractiveness 
I feel rather lively and excitable 
I feel physically attractive 
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Appendix B. Questions of menopausal symptoms modified from the                    
Kupperman Index.  
 
Night sweats 
Hot flushes 
Numbness 
Insomnia 
Irritability, nervousness 
Feeling exhausted 
Depressive mood 
Dizziness 
Weakness, Fatigue 
Aching joints or muscles 
Headaches 
Palpitation 
Vaginal or genital dryness 
Edema 
Shortness of breath 
Dryness of mouth 
A lump-feeling in the throat 
Nausea 
Trembling 
 
 
 
Appendix C. General health. 
 
1. Verrattuna keskimääräiseen terveydentilaani viimeisten 12 kuukauden 
aikana, terveydentilani on tällä hetkellä ... 
 
1 parempi 
2 suunnilleen sama 
3 huonompi 
 
2. Alla on asteikko, johon pyydämme teitä merkitsemään tämänhetkisen 
terveydentilanne. Vetäkää viiva siihen kohtaan asteikkoa, joka 
parhaiten kuvaa terveydentilaanne tänään. 
Parasta terveydentilaa, jonka voitte kuvitella merkitään 100 :lla, 
huonointa 0 :lla. 
 
 
0           10          20          30          40          50          60          70          80          90          100 
|--------|---------|---------|----------|---------|---------|----------|---------|---------|----------| 
 
 
Huonoin kuviteltavissa 
oleva terveydentila 
Paras kuviteltavissa 
oleva terveydentila 
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Appendix D. Items of the McCoy Female Sexuality Questionnaire answered on a 
seven-point Likert scale. 
 
 
Sexual satisfaction 
Enjoyment of sexual activity 
Satisfaction with frequency of sexual activity 
Frequency of sexual thoughts and fantasies 
Excitement/arousal during sexual activity 
Frequency of orgasm 
Sexual problems 
Insufficient lubrication 
Painful sexual intercourse 
Satisfaction with the partner 
Level of sexual interest 
Satisfaction with partner as lover 
Satisfaction with partner as friend 
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Appendix E. Premenstrual symptom screening tool (PSST). 
Tässä osiossa kartoitamme esiintyikö Teillä Kuukautisia edeltävään oireyhtymään (engl. 
Premenstrual syndrome, PMS) liittyviä oireita. Pyydämme Teitä muistelemaan 
mahdollisimman tarkasti aikaa, jolloin Teillä vielä oli kuukautiset (esim. 30-40-vuotiaana) ja 
vastaamaan seuraaviin kysymyksiin sen perusteella.  Jos mahdollista, niin vastatkaa 
sellaisen ajanjakson pohjalta, jolloin Teillä oli luonnollinen kuukautiskierto ilman mitään 
hormonaalista ehkäisyä tai muuta hormonihoitoa. 
Merkitse rasti (x) sopivaan ruutuun 
Oliko Teillä joitakin seuraavista kuukautisia edeltävistä oireista, jotka alkavat ennen 
kuukautisvuotoa ja loppuvat ensimmäisten vuotopäivien aikana? 
    Oire Ei lainkaan Lievä Kohtalainen Vaikea 
1. Vihaisuus/ärtyneisyys     
2. Ahdistuneisuus/jännittyneisyys     
3. Itkuisuus/hylätyksi tulemisen tunne     
4. Masentunut mieliala/toivottomuus     
5. Kiinnostuksen väheneminen työasioihin     
6. Kiinnostuksen väheneminen kotitöihin/kotiasioihin     
7. Kiinnostuksen väheneminen sosiaalisiin  
    aktiviteetteihin 
    
8. Keskittymisvaikeus     
9. Uupumus/energianpuute     
10. Ylensyöminen/ruuanhimot     
11. Unettomuus     
12. Uneliaisuus (lisääntynyt unen tarve)     
13. Musertuneisuuden tunne/olla poissa tolaltaan     
14. Fyysisiä oireita: rintojen arkuus, päänsärky,  
       nivel- tai lihaskipu, turvotus, painonlisäys 
    
Ovatko yllä olevassa taulukossa listatut oireesi vaikuttaneet: 
  Ei lainkaan Lievästi Kohtalaisesti Vaikeasti 
A. Sinun työtehokkuuteesi ja tuotteliaisuuteesi     
B. Sinun suhteisiin työtovereihisi     
C. Sinun suhteisiin perheeseesi     
D. Sinun sosiaalisen elämäsi aktiviteetteihin     
E. Sinun kodin velvoitteiden hoitamiseen     
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Ympyröikää kohdallanne sopivin vaihtoehto tai kirjoittakaa vastaus sille varattuun tilaan. 
Oliko kuukautiskiertonne pääsääntöisesti säännöllinen (23-35 päivää)? 
1. Ei 2. Kyllä 
 Käytittekö jotain hormonaalista hoitoa tai hormonaalista ehkäisyä kierron 
säännöllistämiseksi? 
1. En 2. Kyllä, mitä 
valmisteita________________________________________________________ 
Jos Teillä oli PMS-oireita, minkä ikäisenä ne alkoivat? ____________________________ 
vuotiaana 
Jos Teillä oli PMS-oireita, minkä ikäisenä ne loppuivat? ___________________________ 
vuotiaana 
Esiintyikö Teillä kuumia aaltoja (vaihdevuosien kuumia aaltoja muistuttavia) 
kuukautiskierron lopulla (ennen kuukautisvuodon alkua)? 
1. Ei 2. Kyllä 
Hakeuduitteko lääkärin vastaanotolle mahdollisten PMS-oireidenne takia? 
1. En 2. Kyllä 
Jos, niin määrättiinkö teille jotain hoitoa PMS-oireisiin? 
1. Ei 2. Kyllä, mitä 
valmisteita________________________________________________________ 
Onko teillä todettu masennusta tai muuta psyykkistä sairautta? 
1. Ei 2. Kyllä, vuonna________, 
mikä__________________________________________________ 
Oletteko joskus käyttänyt masennuslääkitystä? 
1. En 2. Kyllä, vuonna________, mitä 
valmistetta________________________________________ 
 
 
Kiitos vastauksistanne! 
